Patent application title: GENES INVOLVED IN INFLAMMATORY BOWEL DISEASES AND USE THEREOF
Jean Pierre Hugot (Paris, FR)
Gilles Thomas (Paris, FR)
Mohamed Zouali (Bagneux, FR)
Suzanne Lesage (Sainte-Honorine, FR)
Mathias Chamaillard (Joue-Les-Tours, FR)
FONDATION JEAN DAUSSET-CEPH
IPC8 Class: AC07H2104FI
Class name: Library, per se (e.g., array, mixture, in silico, etc.) library containing only organic compounds nucleotides or polynucleotides, or derivatives thereof
Publication date: 2013-02-07
Patent application number: 20130035260
The invention concerns genes involved in inflammatory and/or immune
diseases and some cancers, in particular intestinal cryptogenic
inflammatory diseases, and proteins coded by said genes. The invention
also concerns methods for diagnosing inflammatory diseases.
26. A purified or isolated nucleic acid probe, wherein said nucleic acid probe is specific for a variant nucleic acid sequence selected from the group consisting of SEQ ID NO:3 having a C to T mutation at nucleotide 16467, SEQ ID NO:3 having a G to C mutation at nucleotide 27059, and SEQ ID NO:3 having a C insertion at nucleotide 34296.
27. The nucleic acid probe of claim 26, wherein said nucleic acid probe is specific for SEQ ID NO:3 having a C to T mutation at nucleotide 16467.
28. The nucleic acid probe of claim 26, wherein said nucleic acid probe is specific for SEQ ID NO:3 having a G to C mutation at nucleotide 27059.
29. The nucleic acid probe of claim 26, wherein said nucleic acid probe is specific for SEQ ID NO:3 having a C insertion at nucleotide 34296.
30. The nucleic acid probe of claim 26, wherein said nucleic acid probe is about 15 to 30 nucleotides in length.
31. The nucleic acid probe of claim 26, wherein said nucleic acid probe comprises a detectable label.
32. The nucleic acid probe of claim 31, wherein said detectable label is selected from the group consisting of a radioactive isotope, a ligand, and a luminescent agent.
33. The nucleic acid probe of claim 32, wherein said ligand is selected from the group consisting of biotin, avidin, streptavidin, dioxygenin, a hapten, and a dye.
34. The nucleic acid probe of claim 32, wherein said luminescent agent is selected from the group consisting of a radioluminescent agent, a chemiluminescent agent, a bioluminescent agent, a fluorescent agent, and a phosphorescent agent.
35. The nucleic acid probe of claim 26, wherein said nucleic acid probe is immobilized on a support.
36. A kit comprising the nucleic acid probe of claim 26.
37. The kit of claim 36, wherein said kit comprises nucleic acid probes specific for at least two of said variant nucleic acid sequences.
38. The kit of claim 36, wherein said kit comprises nucleic acid probes specific for three of said variant nucleic acid sequences.
39. A DNA chip comprising the nucleic acid probe of claim 26.
40. The DNA chip of claim 39, wherein said DNA chip comprises nucleic acid probes specific for at least two of said variant nucleic acid sequences.
41. The DNA chip of claim 39, wherein said DNA chip comprises nucleic acid probes specific for three of said variant nucleic acid sequences.
CROSS-REFERENCES TO RELATED APPLICATIONS
 This application is a continuation of U.S. application Ser. No. 12/370,543, filed Feb. 12, 2009, which application is a continuation of U.S. application Ser. No. 10/240,046, filed Jan. 15, 2003, now U.S. Pat. No. 7,592,437 which issued on Sep. 22, 2009, which application was a National Stage application of PCT/FR01/00935, filed Mar. 27, 2001, which application claims priority to FR 0003832, filed Mar. 27, 2000, all of which are incorporated by reference in their entirety.
 The present invention relates to genes involved in inflammatory and/or immune diseases and certain cancers, in particularly cryptogenetic inflammatory bowel diseases, and also to the proteins encoded by these genes. The present invention also relates to methods for diagnosing inflammatory diseases.
 Cryptogenetic inflammatory bowel diseases (IBDs) are diseases characterized by an inflammation of the digestive tract, the cause of which is unknown. Depending on the location and the characteristics of the inflammation, two different nosological entities are distinguished: ulcerative colitis (UC) and Crohn's disease (CD). UC was described by S Wilkes in 1865, whereas the first case of regional ileitis was reported by Crohn in 1932. In reality, it is possible that these two diseases go back much further.
 IBDs are chronic diseases which evolve throughout life and which affect approximately 1 to 2 individuals per 1000 inhabitants in western countries, which represents between 60000 and 100000 individuals suffering from these diseases in France. They are diseases which appear in young individuals (peak instance is in the third decade), progressing via attacks interspersed with remissions, with frequent complications such as undernutrition, retarded growth in children, bone demineralization and, in the end, malignant degeneration to colon cancer. No specific treatment exists. Conventional therapeutics make use of anti-inflammatories, of immunosuppressors and of surgery. All these therapeutic means are, themselves, a source of considerable iatrogenic morbidity. For all these reasons, IBDs appear to be a considerable public health problem.
 The etiology of IBDs is currently unknown. Environmental factors are involved in the occurrence of the disease, as witnessed by the secular increase in incidence of the disease and the incomplete concordance in monozygous twins. The only environmental risk factors currently known are 1) tobacco, the role of which is harmful in CD and beneficial in UC, and 2) appendectomy which has a protective role for UC.
 Genetic predisposition has been suspected for a long time due to the existence of ethnic and familial aggregation of these diseases. In fact, IBDs are more common in the Caucasian population, and in particular in the Jewish population of central Europe. Familial forms represent from 6 to 20% of IBD cases. They are particularly common when the disease begins early. However, it is studies in twins which have made it possible to confirm the genetic nature of these diseases. In fact, the concordance rate between twins for these diseases is greater in monozygous twins than in dizygous twins, which pleads strongly in favor of a hereditary component to IBDs, in particular to CD. In all probability, IBDs are complex genetic diseases involving several different genes, interacting with one another and with environmental factors. IBDs can therefore be classified within the context of multifactor diseases.
 Two major strategies have been developed in order to demonstrate the IBD-susceptibility genes. The first is based on the analysis of genes which are candidates for physiopathological reasons. Thus, many genes have been proposed as potentially important for IBDs. They are often genes which have a role in inflammation and the immune response. Mention may be made of the HLA, TAP, TNF and MICA genes, lymphocyte T receptor, ICAM1, interleukin 1, CCR5, etc. Other genes participate in diverse functions, such as GAI2, motilin, MRAMP, HMLH1, etc. In reality, none of the various candidate genes studied has currently definitively proved itself to have a role in the occurrence of IBDs.
 The recent development of human genome maps using highly polymorphic genetic markers has enabled geneticists to develop a nontargeted approach over the entire genome. This approach, also called reverse genetics or positional cloning, makes no hypothesis regarding the genes involved in the disease and attempts to discover them through systematic screening of the genome. The method most used for complex genetic diseases is based on studying identity by decendance of the affected individuals of the same family. This value is calculated for a large number (300-400) of polymorphism markers distributed evenly (every 10cM) over the genome). In the case of excess identity between affected individuals, the marker(s) tested indicate(s) a region supposed to contain a gene for susceptibility to the disease. In the case of complex genetic diseases, since the model underlying the genetic predisposition (number of genes and relative importance of each of them) is unknown, the statistical methods to be used will have to be adjusted.
 The present invention relates to the demonstration of the nucleic acid sequence of genes involved in IBDs, and other inflammatory diseases, and also the use of these nucleic acid sequences.
 In the context of the present invention, preliminary studies by the inventors have already made it possible to locate a CD-susceptibility gene. Specifically, the inventors (Hugot et al., 1996) have shown that a CD-susceptibility gene is located in the pericentromeric region of chromosome 16 (FIG. 1). It was the first gene for susceptibility to a complex genetic disease located by positional cloning and satisfying the strict criteria proposed in the literature (Lander and Kruglyak, 1995). This gene was named IBD1 (for inflammatory bowel disease 1). Since then, other locations have been proposed by other authors, in particular on chromosomes 12, 1, 3, 6 and 7 (Satsangi et al., 1996; Cho et al., 1998). Although they have been located, it has currently not been possible to identify any of these IBD-susceptibility genes.
 Some authors have not been able to replicate this location (Rioux et al., 1998). This is not, however, surprising in the case of complex genetic diseases in which genetic heterogeneity is probable.
 It is interesting to note that, according to the same approach of positional cloning, locations have also been proposed on chromosome 16 for several immune and inflammatory diseases, such as ankylosing spondylarthritis, Blau's syndrome, psoriasis, etc. (Becker et al., 1998; Tromp et al., 1996). All these diseases may then share the same gene (or the same group of genes) located on chromosome 16.
 A maximum of genetic linkage tests is virtually always located at the same position, in the region of D16S409 or D16S411, separated only by 2cM. This result contradicts the considerable size (usually greater than 20cM) of the confidence interval which can be attributed to the genetic location according to an approach using nonparametric linkage analyses.
 Comparison of the statistical tests used in the studies by the inventors shows that the tests based on complete identity by decendance (Tz2) are better than the tests based on the mean of identity by decendance (Tz) (FIG. 1). Such a difference can be explained by a recessive effect of IBD1.
 Several genes known to be in the pericentromeric region of chromosome 16, such as the interleukin 4 receptor, CD19, CD43 or CD11, appear to be good potential candidates for CD. Preliminary results do not however plead in favor of these genes being involved in CD.
 In particular, the present invention provides not only the sequence of IBD1 gene, but also the partial sequence of another gene, called IBD1prox due to it being located in proximity to IBD, and demonstrated as reported in the examples below. These genes, the cDNA sequence of which corresponds, respectively, to SEQ ID No. 1 and SEQ ID No. 4, are therefore potentially involved in many inflammatory and/or immune diseases and also in cancers.
 The peptide sequence expressed by the IBD1 and IBD1prox genes is represented by SEQ ID No. 2 and SEQ ID No. 5, respectively; the genomic sequence of these genes is represented by SEQ ID No. 3 and SEQ ID No. 6, respectively.
 Thus, a subject of the present invention is a purified or isolated nucleic acid, characterized in that it Comprises a nucleic acid sequence chosen from the following group of sequences:  a) SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 6;  b) the sequence of a fragment of at least 15 consecutive nucleotides of a sequence chosen from SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4 or SEQ ID No. 6;  c) a nucleic acid sequence having a percentage identity of at least 80%, after optimal alignment, with a sequence defined in a) or b);  d) a nucleic acid sequence which hybridizes, under high stringency conditions, with a nucleic acid sequence defined in a) or b);  e) the complementary sequence or the RNA sequence corresponding to a sequence as defined in a), b), c) or d).
 The nucleic acid sequence according to the invention defined in c) has a percentage identity of at least 80%, after optimal alignment, with a sequence as defined in a) or b) above, preferably 90%, most preferably 98%.
 The terms "nucleic acid", "nucleic acid sequence", "polynucleotide", "oligonucleotide", "polynucleotide sequence" and "nucleotide sequence", terms which will be employed indifferently in the present description, are intended to denote a precise series of nucleotides, which may or may not be modified, making it possible to define a fragment or a region of a nucleic acid, which may or may not comprise unnatural nucleotides, and which may correspond equally to a double-stranded DNA, a single-stranded DNA and transcription products of said DNAs. Thus, the nucleic acid sequences according to the invention also encompass PNAs (Peptide Nucleic Acids), or the like.
 It should be understood that the present invention does not relate to the nucleotide sequences in their natural chromosomal environment, that is to say in the natural state. They are sequences which have been isolated and/or purified, that is to say they have been taken directly or indirectly, for example by copying, their environment having been at least partially modified. Thus, nucleic acids obtained by chemical synthesis are also intended to be denoted.
 For the purpose of the present invention, the term "percentage identity" between two nucleic acid or amino acid sequences is intended to denote a percentage of nucleotides or of amino acid residues which are identical between the two sequences to be compared, obtained after the best alignment, this percentage being purely statistical and the differences between the two sequences being distributed randomly and over their entire length. The term "best alignment" or "optimal alignment" is intended to denote the alignment for which the percentage identity determined as below is highest. Sequence comparisons between two nucleic acid or amino acid sequences are conventionally carried out by comparing these sequences after having aligned them optimally, said comparison being carried out by segment or by "window of comparison" so as to identify and compare local regions of sequence similarity. The optimal alignment of the sequences for the comparison may be carried out, besides manually, by means of the local homology algorithm of Smith and Waterman (1981), by means of the local homology algorithm of Neddleman and Wunsch (1970), by means of the similarity search method of Pearson and Lipman (1988), by means of computer programs using these algorithms (GAP, BESTFIT, BLAST P, BLAST N, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.). In order to obtain the optimal alignment, the BLAST program is preferably used, with the BLOSUM 62 matrix. The PAM or PAM250 matrices may also be used.
 The percentage identity between two nucleic acid or amino acid sequences is determined by comparing these two sequences aligned optimally, the nucleic acid or amino acid sequence to be compared possibly comprising additions or deletions with respect to the reference sequence for optimal alignment between these two sequences. The percentage identity is calculated by determining the number of identical positions for which the nucleotide or the amino acid residue is identical between the two sequences, dividing this number of identical positions by the total number of positions compared and multiplying the resultant number by 100 so as to obtain the percentage identity between these two sequences.
 The expression "nucleic acid sequences having a percentage identity of at least 80%, preferably 90%, more preferably 98%, after optimal alignment with a reference sequence" is intended to denote the nucleic acid sequences which, compared to the reference nucleic acid sequence, have certain modifications, such as in particular a deletion, a truncation, an extension, a chimeric fusion and/or a substitution, in particular of the point type, and the nucleic acid sequence of which exhibits at least 80%, preferably 90%, more preferably 98%, identity, after optimal alignment, with the reference nucleic acid sequence. They are preferably sequences whose complementary sequences are capable of hybridizing specifically with the sequence SEQ ID No. 1 or SEQ ID No. 4 of the invention. Preferably, the specific or high stringency hybridization conditions will be such that they ensure at least 80%, preferably 90%, more preferably 98%, identity, after optimal alignment, between one of the two sequences and the sequence complementary to the other.
 Hybridization under high stringency conditions means that the conditions of temperature and of ionic strength are chosen such that they allow the hybridization between two complementary DNA fragments to be maintained. By way of illustration, high stringency conditions for the hybridization step for the purposes of defining the polynucleotide fragments described above are advantageously as follows.
 The DNA-DNA or DNA-RNA hybridization is carried out in two steps: (1) prehybridization at 42° C. for 3 hours in phosphate buffer (20 mM, pH 7.5) containing 5×SSC (1×SSC corresponds to a solution of 0.15 M NaCl+0.015 M sodium citrate), 50% of formamide, 7% of sodium dodecyl sulfate (SDS), 10×Denhardt's, 5% of dextran sulfate and 1% of salmon sperm DNA; (2) hybridization per se for 20 hours at a temperature which depends on the length of the probe (i.e.: 42° C. for a probe >100 nucleotides in length), followed by 2 washes of 20 minutes at 20° C. in 2×SSC+2% SDS and 1 wash of 20 minutes at 20° C. in 0.1×SSC+0.1% SDS. The final wash is carried out in 0.1×SSC+0.1% SDS for 30 minutes at 60° C. for a probe >100 nucleotides in length. The high stringency hybridization conditions described above for a polynucleotide of defined length may be adjusted by those skilled in the art for longer or shorter oligonucleotides, according to the teaching of Sambrook et al., 1989.
 Among the nucleic acid sequences having a percentage identity of at least 80%, preferably 90%, more preferably 98%, after optimal alignment, with the sequence according to the invention, preference is also given to the variant nucleic acid sequences of SEQ ID No. 1 or of SEQ ID No. 4, or of fragments thereof, that is to say all the nucleic acid sequences corresponding to allelic variants, that is to say individual variations of the sequence SEQ ID No. 1 or SEQ ID No. 4. These natural mutated sequences correspond to polymorphisms present in mammals, in particular in humans and, in particular, to polymorphisms which may lead to the occurrence of a pathological condition. Preferably, the present invention relates to the variant nucleic acid sequences in which the mutations lead to a modification of the amino acid sequence of the polypeptide, or of fragments thereof, encoded by the normal sequence of SEQ ID No. 1 or SEQ ID No. 4.
 The expression "variant nucleic acid sequence" is also intended to denote any RNA or cDNA resulting from a mutation and/or variation of a splice site of the genomic nucleic acid sequence the cDNA of which has the sequence SEQ ID No. 1 or SEQ ID No. 4.
 The invention preferably relates to a purified or isolated nucleic acid according to the present invention, characterized in that it comprises or consists of one of the sequences SEQ ID No. 1 or SEQ ID No. 4, of the sequences complementary thereto, or of the RNA sequences corresponding to SEQ ID No. 1 or SEQ ID No. 4.
 The probes or primers, characterized in that they comprise a sequence of a nucleic acid according to the invention, are also part of the invention.
 Thus, the present invention also relates to the primers or the probes according to the invention which may make it possible in particular to demonstrate or to distinguish the variant nucleic acid sequences, or to identify the genomic sequence of the genes the cDNA of which is represented by SEQ ID No. 1 or SEQ ID No. 4, in particular using an amplification method such as the PCR method or a related method.
 The invention also relates to the use of a nucleic acid sequence according to the invention, as a probe or primer, for detecting, identifying, assaying or amplifying a nucleic acid sequence.
 According to the invention, the polynucleotides which can be used as a probe or as a primer in methods for detecting, identifying, assaying or amplifying a nucleic acid sequence are a minimum of 15 bases, preferably 20 bases, or better still 25 to 30 bases in length.
 The probes and primers according to the invention may be labeled directly or indirectly with a radioactive or nonradioactive compound using methods well known to those skilled in the art, in order to obtain a detectable and/or quantifiable signal.
 The polynucleotide sequences according to the invention which are unlabeled can be used directly as a probe or primer.
 The sequences are generally labeled so as to obtain sequences which can be used in many applications. The primers or the probes according to the invention are labeled with radioactive elements or with nonradio-active molecules.
 Among the radioactive isotopes used, mention may be made of 32P, 33P, 35S, 3H or 125I. The nonradioactive entities are selected from ligands such as biotin, avidin, streptavidin or dioxygenin, haptens, dyes and luminescent agents, such as radioluminescent, chemiluminescent, bioluminescent, fluorescent or phosphorescent agents.
 The polynucleotides according to the invention may thus be used as a primer and/or probe in methods using in particular the PCR (polymerase chain reaction) technique (Rolfs et al., 1991). This technique requires choosing pairs of oligonucleotide primers bordering the fragment which must be amplified. Reference may, for example, be made to the technique described in U.S. Pat. No. 4,683,202. The amplified fragments can be identified, for example after agarose or polyacrylamide gel electrophoresis, or after a chromatographic technique such as gel filtration or ion exchange chromatography, and then sequenced. The specificity of the amplification can be controlled using, as primers, the nucleotide sequences of polynucleotides of the invention and, as matrices, plasmids containing these sequences or else the derived amplification products. The amplified nucleotide fragments may be used as reagents in hybridization reactions in order to demonstrate the presence, in a biological sample, of a target nucleic acid of sequence complementary to that of said amplified nucleotide fragments.
 The invention is also directed toward the nucleic acids which can be obtained by amplification using primers according to the invention.
 Other techniques for amplifying the target nucleic acid may advantageously be employed as an alternative to PCR (PCR-like) using a pair of primers of nucleotide sequences according to the invention. The term "PCR-like" is intended to denote all the methods using direct or indirect reproductions of nucleic acid sequences, or else in which the labeling systems have been amplified; these techniques are of course, known. In general, they involve amplifying the DNA with a polymerase; when the sample of origin is an RNA a reverse transcription should be carried out beforehand. A large number of methods currently exist for this amplification, such as, for example, the SDA (strand displacement amplification) technique (Walker et al., 1992), the TAS (transcription-based amplification system) technique described by Kwoh et al. (1989), the 3SR (self-sustained sequence replication) technique described by Guatelli et al. (1990), the NASBA (nucleic acid sequence based amplification) technique described by Kievitis et al. (1991), the TMA (transcription mediated amplification) technique, the LCR (ligase chain reaction) technique described by Landegren et al. (1988), the RCR (repair chain reaction) technique described by Segev (1992), the CPR (cycling probe reaction) technique described by Duck et al. (1990), and the Q-beta-replicase amplification technique described by Miele et al. (1983). Some of these techniques have since been improved.
 When the target polynucleotide to be detected is an mRNA, an enzyme of the reverse transcriptase type is advantageously used, prior to carrying out an amplification reaction using the primers according to the invention or to carrying out a method of detection using the probes of the invention, in order to obtain a cDNA from the mRNA contained in the biological sample. The cDNA obtained will then serve as a target for the primers or the probes used in the amplification or detection method according to the invention.
 The probe hybridization technique may be carried out in many ways (Matthews et al., 1988). The most general method consists in immobilizing the nucleic acid extracted from the cells of various tissues or from cells in culture, on a support (such as nitrocellulose, nylon or polystyrene), and in incubating the immobilized target nucleic acid with the probe, under well-defined conditions. After hybridization, the excess probe is removed and the hybrid molecules formed are detected using the appropriate method (measuring the radioactivity, the fluorescence or the enzymatic activity linked to the probe).
 According to another embodiment of the nucleic acid probes according to the invention, the latter may be used as capture probes. In this case, a probe, termed "capture probe", is immobilized on a support and is used to capture, by specific hybridization, the target nucleic acid obtained from the biological sample to be tested, and the target nucleic acid is then detected using a second probe, termed "detection probe", labeled with a readily detectable element.
 Among the advantageous nucleic acid fragments, mention should thus be made in particular of antisense oligonucleotides, i.e. oligonucleotides, the structure of which ensures, by hybridization with the target sequence, inhibition of expression of the corresponding product. Mention should also be made of sense oligonucleotides, which, by interacting with proteins involved in regulating the expression of the corresponding product, will induce either inhibition or activation of this expression.
 In both cases (sense and antisense), the oligo-nucleotides of the invention may be used in vitro and in vivo.
 The present invention also relates to an isolated polypeptide, characterized in that it comprises a polypeptide chosen from:  a) a polypeptide of sequence SEQ ID No. 2 or SEQ ID No. 5;  b) a variant polypeptide of a polypeptide of sequence defined in a);  c) a polypeptide homologous to a polypeptide defined in a) or b), comprising at least 80% identity with said polypeptide of a);  d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);  e) a biologically active fragment of a polypeptide defined in a), b) or c).
 For the purpose of the present invention, the term "polypeptide" is intended to denote proteins or peptides.
 The expression "biologically active fragment" is intended to mean a fragment having the same biological activity as the peptide fragment from which it is deduced, preferably within the same order of magnitude (to within a factor of 10). Thus, the examples show that the IBD1 protein (SEQ ID No. 2) has a potential role in apoptosis phenomena. A biologically active fragment of the IBD1 protein therefore consists of a polypeptide derived from SEQ ID No. 2, also having a role in apoptosis. The examples below propose biological functions for the IBD1 and IBD1prox proteins, as a function of the peptide domains of these proteins, and thus allow those skilled in the art to identify the biologically active fragments.
 Preferably, a polypeptide according to the invention is a polypeptide consisting of the sequence SEQ ID No. 2 (corresponding to the protein encoded by the IBD1 gene) or of the sequence SEQ ID No. 5 (corresponding to the protein encoded by IBD1prox) or of a sequence having at least 80% identity with SEQ ID No. 2 or SEQ ID No. 5 after optimal alignment.
 The sequence of the polypeptide has a percentage identity of at least 80%, after optimal alignment, with the sequence SEQ ID No. 2 or SEQ ID No. 5, preferably 90%, more preferably 98%.
 The expression "polypeptide, the amino acid sequence of which has a percentage identity of at least 80%, preferably 90%, more preferably 98%, after optimal alignment, with a reference sequence" is intended to denote the polypeptides having certain modifications compared to the reference polypeptide, such as in particular one or more deletions and/or truncations, an extension, a chimeric fusion and/or one or more substitutions.
 Among the polypeptides, the amino acid sequence of which has a percentage identity of at least 80%, preferably 90%, more preferably 98%, after optimal alignment, with the sequence SEQ ID No. 2 or SEQ ID No. 5 or with a fragment thereof according to the invention, preference is given to the variant polypeptides encoded by the variant nucleic acid sequences as defined previously, in particular the polypeptides, the amino acid sequence of which has at least one mutation corresponding in particular to a truncation, deletion, substitution and/or addition of at least one amino acid residue compared with the sequence SEQ ID No. 2 or SEQ ID No. 5 or with a fragment thereof, more preferably the variant polypeptides having a mutation associated with the pathological condition.
 The present invention also relates to the cloning and/or expression vectors comprising a nucleic acid or encoding a polypeptide according to the invention. Such a vector may also contain the elements required for the expression and, optionally, the secretion of the polypeptide in a host cell. Such a host cell is also a subject of the invention.
 The vectors characterized in that they comprise a promoter and/or regulator sequence according to the invention are also part of the invention.
 Said vectors preferably comprise a promoter, translation initiation and termination signals, and also regions suitable for regulating transcription. It must be possible for them to be maintained stably in the cell and they may optionally contain particular signals specifying secretion of the translated protein.
 These various control signals are chosen as a function of the cellular host used. To this effect, the nucleic acid sequences according to the invention may be inserted into vectors which replicate autonomously in the chosen host, or vectors which integrate in the chosen host.
 Among the systems which replicate autonomously, use is preferably made, depending on the host cell, of systems of the plasmid or viral type, the viral vectors possibly being in particular adenoviruses (Perricaudet et al., 1992), retroviruses, lentiviruses, poxviruses or herpesviruses (Epstein et al., 1992). Those skilled in the art are aware of the technology which can be used for each of these systems.
 When integration of the sequence into the chromosomes of the host cell is desired, use may be made, for example, of systems of the plasmid or viral type; such viruses are, for example, retroviruses (Temin, 1986), or AAVs (Carter, 1993).
 Among the nonviral vectors, preference is given to naked polynucleotides such as naked DNA or naked RNA according to the technology developed by the company VICAL, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs) for expression in yeast, mouse artificial chromosomes (MACs) for expression in murine cells and, preferably, human artificial chromosomes (HACs) for expression in human cells.
 Such vectors are prepared according to the methods commonly used by those skilled in the art, and the clones resulting therefrom can be introduced into a suitable host using standard methods, such as, for example, lipofection, electroporation, heat shock, transformation after chemical permeabilization of the membrane, or cell fusion.
 The invention also comprises host cells, in particular the eukaryotic and prokaryotic cells, transformed with the vectors according to the invention, and also the transgenic animals, preferably the mammals, except humans, comprising one of said transformed cells according to the invention. These animals may be used as models, for studying the etiology of inflammatory and/or immune diseases, in particular of the inflammatory diseases of the digestive tract, or for studying cancers.
 Among the cells which can be used for the purpose of the present invention, mention may be made of bacterial cells (Olins and Lee, 1993), but also yeast cells (Buckholz, 1993) as well as animal cells, in particular mammalian cell cultures (Edwards and Aruffo, 1993), and especially Chinese hamster ovary (CHO) cells. Mention may also be made of insect cells in which it is possible to use methods employing, for example, baculo viruses (Luckow, 1993). A preferred cellular host for expressing the proteins of the invention consists of COS cells.
 Among the mammals according to the invention, animals such as rodents, in particular mice, rats or rabbits, expressing a polypeptide according to the invention are preferred.
 Among the mammals according to the invention, preference is also given to animals such as mice, rats or rabbits, characterized in that the gene encoding the protein of sequence SEQ ID No. 2 or SEQ ID No. 5, or the sequence of which is encoded by the homologous gene in these animals, is not functional, has been knocked out or has at least one mutation.
 These transgenic animals are obtained, for example, by homologous recombination on embryonic stem cells, transfer of these stem cells to embryos, selection of the chimeras affected in the reproductive lines, and growth of said chimeras.
 The transgenic animals according to the invention may thus overexpress the gene encoding the protein according to the invention, or their homologous gene, or express said gene into which a mutation is introduced. These transgenic animals, in particular mice, are obtained, for example, by transfection of a copy of this gene under the control of a promoter which is strong and ubiquitous, or selective for a tissue type, or after viral transcription.
 Alternatively, the transgenic animals according to the invention may be made deficient for the gene encoding one of the polypeptides of sequence SEQ ID No. 2 or SEQ ID No. 5, or their homologous genes, by inactivation using the LOXP/CRE recombinase system (Rohlmann et al., 1996) or any other system for inactivating the expression of this gene.
 The cells and mammals according to the invention can be used in a method for producing a polypeptide according to the invention, as described below, and may also be used as a model for analysis.
 The cells or mammals transformed as described above can also be used as models in order to study the interactions between the polypeptides according to the invention, and the chemical or protein compounds involved directly or indirectly in the activities of the polypeptides according to the invention, this being in order to study the various mechanisms and interactions involved.
 They may in particular be used for selecting products which interact with the polypeptides according to the invention, in particular the protein of sequence SEQ ID No. 2 or SEQ ID No. 5 or variants thereof according to the invention, as a cofactor or as an inhibitor, in particular a competitive inhibitor, or which have an agonist or antagonist activity with respect to the activity of the polypeptides according to the invention. Preferably, said transformed cells or transgenic animals are used as a model in particular for selecting products for combating pathological conditions associated with abnormal expression of this gene.
 The invention also relates to the use of a cell, of a mammal or of a polypeptide according to the invention, for screening chemical or biochemical compounds which may interact directly or indirectly with the polypeptides according to the invention, and/or which are capable of modulating the expression or the activity of these polypeptides.
 Similarly, the invention also relates to a method for screening compounds capable of interacting, in vitro or in vivo, with a nucleic acid according to the invention, using a nucleic acid, a cell or a mammal according to the invention, and detecting the formation of a complex between the candidate compounds and the nucleic acid according to the invention.
 The compounds thus selected are also subjects of the invention.
 The invention also relates to the use of a nucleic acid sequence according to the invention, for synthesizing recombinant polypeptides.
 The method for producing a polypeptide of the invention in recombinant form, which is itself included in the present invention, is characterized in that the transformed cells, in particular the cells or mammals of the present invention, are cultured under conditions which allow the expression of a recombinant polypeptide encoded by a nucleic acid sequence according to the invention, and in that said recombinant polypeptide is recovered.
 The recombinant polypeptides, characterized in that they can be obtained using said method of production, are also part of the invention.
 The recombinant polypeptides obtained as indicated above can be in both glycosylated and nonglycosylated form, and may or may not have the natural tertiary structure.
 The sequences of the recombinant polypeptides may also be modified in order to improve their solubility, in particular in aqueous solvents.
 Such modifications are known to those skilled in the art, such as, for example, deletion of hydrophobic domains or substitution of hydrophobic amino acids with hydrophilic amino acids.
 These polypeptides may be produced using the nucleic acid sequences defined above, according to the techniques for producing recombinant polypeptides known to those skilled in the art. In this case, the nucleic acid sequence used is placed under the control of signals which allow its expression in a cellular host.
 An effective system for producing a recombinant polypeptide requires having a vector and a host cell according to the invention.
 These cells can be obtained by introducing into host cells a nucleotide sequence inserted into a vector as defined above, and then culturing said cells under conditions which allow the replication and/or expression of the transfected nucleotide sequence.
 The methods used for purifying a recombinant polypeptide are known to those skilled in the art. The recombinant polypeptide may be purified from cell lysates and extracts or from the culture medium supernatant, by methods used individually or in combination, such as fractionation, chromatography methods, immunoaffinity techniques using specific monoclonal or polyclonal antibodies, etc.
 The polypeptides according to the present invention can also be obtained by chemical synthesis using one of the many known forms of peptide synthesis, for example techniques using solid phases (see in particular Stewart et al., 1984) or techniques using partial solid phases, by fragment condensation or by conventional synthesis in solution.
 The polypeptides obtained by chemical synthesis and which may comprise corresponding unnatural amino acids are also included in the invention.
 The mono- or polyclonal antibodies, or fragments thereof, chimeric antibodies or immunoconjugates, characterized in that they are capable of specifically recognizing a polypeptide according to the invention, are part of the invention.
 Specific polyclonal antibodies may be obtained from a serum of an animal immunized against the polypeptides according to the invention, in particular produced by genetic recombination or by peptide synthesis, according to the usual procedures.
 The advantage of antibodies which specifically recognize certain polypeptides, variants or immunogenic fragments thereof according to the invention is in particular noted.
 The mono- or polyclonal antibodies, or fragments thereof, chimeric antibodies or immunoconjugates characterized in that they are capable of specifically recognizing the polypeptides of sequence SEQ ID No. 2 or SEQ ID No. 5 are particularly preferred.
 The specific monoclonal antibodies may be obtained according to the conventional method of hybridoma culture described by Kohler and Milstein (1975).
 The antibodies according to the invention are, for example, chimeric antibodies, humanized antibodies, or Fab or F(ab')2 fragments. They may also be in the form of immunoconjugates or of labeled antibodies, in order to obtain a detectable and/or quantifiable signal.
 The invention also relates to methods for detecting and/or purifying a polypeptide according to the invention, characterized in that they use an antibody according to the invention.
 The invention also comprises purified polypeptides, characterized in that they are obtained using a method according to the invention.
 Moreover, besides their use for purifying the polypeptides, the antibodies of the invention, in particular the monoclonal antibodies, may also be used for detecting these polypeptides in a biological sample.
 They thus constitute a means for the immunocytochemical or immunohistochemical analysis of the expression of the polypeptides according to the invention, in particular the polypeptides of sequence SEQ ID No. 2 or SEQ ID No. 5, or a variant thereof, on specific tissue sections, for example using immunofluorescence, gold labeling and/or enzymatic immunoconjugates.
 They may in particular make it possible to demonstrate abnormal expression of these polypeptides in the biological specimens or tissues.
 More generally, the antibodies of the invention may advantageously be used in any situation where the expression of a polypeptide according to the invention, normal or mutated, must be observed.
 Thus, a method for detecting a polypeptide according to the invention, in a biological sample, comprising the Steps of bringing the biological sample into contact with an antibody according to the invention and demonstrating the antigen-antibody complex formed, is also a subject of the invention, as is a kit for carrying out such a method. Such a kit in particular contains:  a) a monoclonal or polyclonal antibody according to the invention;  b) optionally, reagents for constituting a medium suitable for the immunoreaction;  c) the reagents for detecting the antigen-antibody complex produced during the immunoreaction.
 The antibodies according to the invention may also be used in the treatment of an inflammatory and/or immune disease, or of a cancer, in humans, when abnormal expression of the IBD1 gene or of the IBD1prox gene is observed. Abnormal expression means overexpression or the expression of a mutated protein.
 These antibodies may be obtained directly from human serum, or may be obtained from animals immunized with polypeptides according to the invention, and then "humanized", and may be used as such or in the preparation of a medicinal product intended for the treatment of the abovementioned diseases.
 The methods for determining an allelic variability, a mutation, a deletion, a loss of heterozygocity or any genetic abnormability of the gene according to the invention, characterized in that they use a nucleic acid sequence, a polypeptide or an antibody according to the invention, are also part of the invention.
 The invention in fact provides the sequence of the IBD1 and IBD1prox genes involved in inflammatory and/or immune diseases, and in particular IBDs. One of the teachings of the invention is to specify the mutations, in these nucleic acid or polypeptide sequences, which are associated with a phenotype corresponding to one of these inflammatory and/or immune diseases.
 These mutations can be detected directly by analysis of the nucleic acid and of the sequences according to the invention (genomic DNA, RNA or cDNA), but also via the polypeptides according to the invention. In particular, the use of an antibody according to the invention which recognizes an epitope bearing a mutation makes it possible to distinguish between a "healthy" protein and a protein "associated with a pathological condition".
 Thus, the study of the IBD1 gene in various inflammatory and/or immune human diseases thus shows that sequence variants of this gene exist in Crohn's disease, ulcerative colitis and Blau's syndrome, as demonstrated by the examples. These sequence variations result in considerable variations in the deduced protein sequence. In fact, they are either located on very conserved sites of the protein in important functional domains, or they result in the synthesis of a truncated protein. It is therefore extremely probable that these deleterious modifications lead to a modification of the function of the protein and therefore have a causal effect in the occurrence of these diseases.
 The variety of diseases in which these mutations are observed suggests that the IBD1 gene is potentially important in many inflammatory and/or immune diseases. This result should be compared with the fact that the pericentromeric region of chromosome 16 has been described as containing genes for susceptibility to various human diseases, such as ankylosing spondylarthritis or psoriatic arthropathy. It may therefore be considered that IBD1 has an important role in a large number of inflammatory and/or immune diseases.
 In particular, IBD1 can be associated with granulomatous inflammatory diseases. Blau's syndrome and CD are in fact diseases which are part of this family. It is therefore hoped that variations in the IBD1 gene will be found for the other diseases of the same family (sarcoidosis, Behcet's disease, etc.).
 In addition, the involvement of IBD1 in the cellular pathways leading to apoptosis raises the question of its possible carcinogenic role. In fact, it is expected that a dysregulation of IBD1 may result in a predisposition to cancer. This hypothesis is supported by the fact that a predisposition to colon cancer exists in inflammatory bowel diseases. IBD1 may in part explain this susceptibility to cancer and define new carcinogenic pathways.
 The precise description of the mutations which can be observed in the IBD1 gene thus makes it possible to lay down the foundations of a molecular diagnosis for the inflammatory or immune diseases in which this role is demonstrated. Such an approach, based on searching for mutations in the gene, will make it possible to contribute to the diagnosis of these diseases and possibly to reduce the extent of certain additional examinations which are invasive or expensive. The invention lays down the foundations of such a molecular diagnosis based on searching for mutations in IBD1.
 The molecular diagnosis of inflammatory diseases should also make it possible to improve the nosological classification of these diseases and to more clearly define subgroups of particular diseases by their clinical characteristics, the progressive nature of the disease or the response to certain treatments. By way of example, the dismantling of the existing mutations may thus make it possible to classify the currently undetermined forms of colitis which represent more than 10% of inflammatory bowel diseases. Such an approach will make it possible to propose an early treatment suitable for each patient. In general, such an approach makes it possible to hope that it will eventually be possible to define an individualized treatment for the disease, depending on the genetic area of each disease, including curative and preventive measures.
 In particular, preference is given to a method of diagnosis and/or of prognostic assessment of an inflammatory disease or of a cancer, characterized in that the presence of at least one mutation and/or a deleterious modification of expression of the gene corresponding to SEQ ID No. 1 or SEQ ID No. 4 is determined, using a biological specimen from a patient, by analyzing all or part of a nucleic acid sequence corresponding to said gene. The genes SEQ ID No. 3 or SEQ ID No. 6 may also be studied.
 This method of diagnosis and/or of prognostic assessment may be used preventively (a study of predisposition to inflammatory diseases or to cancer), or in order to serve in establishing and/or confirming a clinical condition in a patient.
 Preferably, the inflammatory disease is an inflammatory disease of the digestive tract, and the cancer is a cancer of the digestive tract (small intestine or colon).
 The teaching of the invention in fact makes it possible to determine the mutations which exhibit a linkage disequilibrium with inflammatory diseases of the digestive tract, and which are therefore associated with such diseases.
 The analysis may be carried out by sequencing all or part of the gene, or by other methods known to those skilled in the art. Methods based on PCR, for example PCR-SSCP, which makes it possible to detect point mutations, may in particular be used.
 The analysis may also be carried out by attaching a probe according to the invention, corresponding to one of the sequences SEQ ID No. 1, 3, 4 or 6, to a DNA chip, and hybridization on these microplates. A DNA chip containing a sequence according to the invention is also one of the subjects of the invention.
 Similarly, a protein chip containing an amino acid sequence according to the invention is also a subject of the invention. Such a protein chip makes it possible to study the interactions between the polypeptides according to the invention and other proteins or chemical compounds, and may thus be useful for screening compounds which interact with the polypeptides according to the invention. The protein chips according to the invention may also be used to detect the presence of antibodies directed against the polypeptides according to the invention in the serum of patients. A protein chip containing an antibody according to the invention may also be used.
 Those skilled in the art are also able to carry out techniques for studying the deleterious modification of the expression of a gene, for example by studying the mRNA (in particular by Northern blotting or with RT-PCR experiments, with probes or primers according to the invention), or the protein expressed, in particular by Western blotting, using antibodies according to the invention.
 The gene tested is preferably the gene of sequence SEQ ID No. 1, the inflammatory disease for which the intention is to predict susceptibility being a disease of the digestive tract, in particular Crohn's disease or ulcerative colitis. If the intention is to detect a cancer, it is preferably colon cancer.
 The invention also relates to methods for obtaining an allele of the IBD1 gene, associated with a detectable phenotype, comprising the following steps:  a) obtaining a nucleic acid sample from an individual expressing said detectable phenotype;  b) bringing said nucleic acid sample into contact with an agent capable of specifically detecting a nucleic acid encoding the IBD1 protein;  c) isolating said nucleic acid encoding the IBD1 protein.
 Such a method may be followed by a step of sequencing all or part of the nucleic acid encoding the IBD1 protein, which makes it possible to predict susceptibility to inflammatory disease or of a cancer.
 The agent capable of specifically detecting a nucleic acid encoding the IBD1 protein is advantageously an oligonucleotide probe according to the invention, which may be made up of DNA, RNA or PNA, which may or may not be modified. The modifications may include radioactive or fluorescent labeling, or may be due to modifications in the bonds between the bases (phosphorothioates or methyl phosphonates, for example). Those skilled in the art are aware of the protocols for isolating a specific DNA sequence. Step b) of the method described above may also be an amplification step as described above.
 The invention also relates to a method for detecting and/or assaying a nucleic acid according to the invention, in a biological sample, comprising the following steps of bringing a probe according to the invention into contact with a biological sample, and detecting and/or assaying the hybrid formed between said polynucleotide and the nucleic acid of the biological sample.
 Those skilled in the art are capable of carrying out such a method, and may in particular use a kit of reagents, comprising:  a) a polynucleotide according to the invention, used as a probe;  b) the reagents required for carrying out a hybridization reaction between said probe and the nucleic acid of the biological sample;  c) the reagents required for detecting and/or assaying the hybrid formed between said probe and the nucleic acid of the biological sample; which is also a subject of the invention.
 Such a kit may also contain positive or negative controls in order to ensure the quality of the results obtained.
 However, in order to detect and/or assay a nucleic acid according to the invention, those skilled in the art may also perform an amplification step using primers chosen from the sequences according to the invention.
 Finally, the invention also relates to the compounds chosen from a nucleic acid, a polypeptide, a vector, a cell or an antibody according to the invention, or the compounds obtained using the screening methods according to the invention, as a medicinal product, in particular for preventing and/or treating an inflammatory and/or immune disease, or a cancer, associated with the presence of at least one mutation of the gene corresponding to SEQ ID No. 1 or SEQ ID No. 4, preferably an inflammatory disease of the digestive tract, in particular Crohn's disease or ulcerative colitis.
 The following examples make it possible to understand more clearly the advantages of the invention, and should not be considered to limit the scope of the invention.
DESCRIPTION OF THE FIGURES
 FIG. 1: Nonparametric genetic linkage tests for Crohn's disease in the pericentromeric region of chromosome 16 (according to Hugot et al., 1996). Multipoint linkage analysis based on identity by decendance for the markers of the pericentromeric region of chromosome 16. The genetic distances between markers were estimated using the CRIMAP program. The lod score (MAPMAKER/SIBS) is indicated on the left-hand figure. Two pseudoprobability tests were developed and reported on the right-hand figure. The first (Tz) is analogous to the test of the means. The second (Tz2) is analogous to the test of the proportion of affected pairs sharing two alleles.
 FIG. 2: Multipoint nonparametric genetic linkage analysis. 78 families with several relatives suffering from Crohn's disease were genotyped for 26 polymorphism markers in the pericentromeric region of chromosome 16. The location of each marker is symbolized by an arrow. The order of the markers and the distance separating them derive from the analysis of the experimental data with the Crimap software. The arrows under the curve indicate the markers SPN, D16S409 and D16S411 used in the first study published (Hugot et al., 1996). The arrows located at the top of the figure correspond to the markers D16S3136, D16S541, D16S3117, D16S416 and D16S770 located at the maximum of the genetic linkage test. The typing data were analyzed using the multipoint nonparametric analysis program of the Genehunter software version 1.3. The maximum NPL score is 3.33 (p=0.0004).
 FIG. 3: Diagrammatic representation of the protein encoded by IBD1. The protein encoded by IBD1 is represented horizontally. The various domains of which it is composed are indicated on the figure with the amino acid reference number corresponding to the start and to the end of each domain. The protein consists of a CARD domain, a nucleotide-binding domain (NBD) and leucine-rich motifs (LRR).
 FIG. 4: Diagrammatic representation of the IBD1/NOD2 protein in three variants associated with CD.
 A: The translation produced deduced from the cDNA sequence of the IBD1 candidate gene is identical to that of NOD2 (Ogura et al., 2000). The polypeptide contains 2 CARD domains (CAspase Recruitment Domains), a nucleotide-binding domain (NBD) and 10 repeats of 27 amino acids, leucine-rich motifs (LRR). The consensus sequence of the ATP/GTP-binding site of the motif A (P loop) of the NBD is indicated with a black circle. The sequence changes encoded by the three main variants associated with CD are SNP 8 (R675W), SNP 12 (G881R) and SNP 13 (frame shift 980). The frame shift changes a leucine codon to a proline codon at position 980, which is immediately followed by a stop codon.
 B: Rare missense variants of NOD2 in 457 CD patients, 159 UC patients and 103 unaffected, unrelated individuals. The positions of the rare missense variants are indicated for the three groups. The scale on the left indicates the number of each variant identified in the groups under investigation and that on the right measures the frequency of the mutation. The allelic frequencies of the polymorphism V928I was not significantly different (0.92:0.08) in the three groups and the corresponding genotypes were in Hardy-Weinberg equilibrium.
Fine Location of IBD1
 The first step toward identifying the IBD1 gene was to reduce the size of the genetic region of interest, initially centered on the marker D16S411 located between D16S409 and D16S419 (Hugot et al., 1996 and FIG. 1). A group of close markers (high resolution genetic map) was used in order to more clearly specify the genetic region, and made it possible to complete the genetic linkage analyses and to search for a genetic linkage disequilibrium with the disease.
 The study related to 78 families comprising at least 2 relatives suffering from CD, which corresponded to 119 affected pairs. The families comprising sick individuals suffering from UC were excluded from the study.
 Twenty-six genetic polymorphism markers of the micro-satellite type were studied. These markers together made up a high resolution map with an average distance between markers of the order of 1cM in the genetic region of interest. The characteristics of the markers studied are given in table 1.
TABLE-US-00001 TABLE 1 Polymorphic markers of the microsatellite type used for the fine location of IBD1 Name of polymorphism Cumulative marker distance (cM) PCR primers D16S3120 0 SEQ ID No. 7 (AFM326vc5) SEQ ID No. 8 D16S298 2.9 SEQ ID No. 9 (AFMa189wg5) SEQ ID No. 10 D16S299 3.4 SEQ ID No. 11 SEQ ID No. 12 SPN 3.9 SEQ ID No. 13 SEQ ID No. 14 D16S383 4.3 SEQ ID No. 15 SEQ ID No. 16 D16S753 4.9 SEQ ID No. 17 (GGAA3G05) SEQ ID No. 18 D16S3044 5.8 SEQ ID No. 19 (AFMa222za9) SEQ ID No. 20 D16S409 5.8 SEQ ID No. 21 (AFM161xa1) SEQ ID No. 22 D16S3105 6.1 SEQ ID No. 23 (AFMb341zc5) SEQ ID No. 24 D16S261 6.8 SEQ ID No. 25 (MFD24) SEQ ID No. 26 D16S540 6.9 SEQ ID No. 27 (GATA7B02) SEQ ID No. 28 D16S3080 7 SEQ ID No. 29 (AFMb068zb9) SEQ ID No. 30 D16S517 7 SEQ ID No. 31 (AFMa132we9) SEQ ID No. 32 D16S411 8 SEQ ID No. 33 (AFM186xa3) SEQ ID No. 34 D16S3035 10.4 SEQ ID No. 35 (AFMa189wg5) SEQ ID No. 36 D16S3136 10.4 SEQ ID No. 37 (AFMa061xe5) SEQ ID No. 38 D16S541 11.4 SEQ ID No. 39 (GATA7E02) SEQ ID No. 40 D16S3117 11.5 SEQ ID No. 41 (AFM288wb1) SEQ ID No. 42 D16S416 12.4 SEQ ID No. 43 (AFM210yg3) SEQ ID No. 44 D16S770 13.2 SEQ ID No. 45 (GGAA20G02) SEQ ID No. 46 D16S2623 15 SEQ ID No. 47 (GATA81B12) SEQ ID No. 48 D16S390 16.5 SEQ ID No. 49 SEQ ID No. 50 D16S419 20.4 SEQ ID No. 51 (AFM225zf2) SEQ ID No. 52 D16S771 21.8 SEQ ID No. 53 (GGAA23C09) SEQ ID No. 54 D16S408 25.6 SEQ ID No. 55 (AFM137xf8) SEQ ID No. 56 D16S508 38.4 SEQ ID No. 57 (AFM304xf1) SEQ ID No. 58
 Each marker is listed according to international nomenclature and mostly by the name proposed by the laboratory of origin. The markers appear according to their order on the chromosome (from 16p to 16q). The genetic distance between the markers (in Kosambi centiMorgans, calculated from the experimental data using the Crimap program) is indicated in the second column. The first polymorphic marker is taken randomly as a reference point. The oligonucleotides which were used for the polymerase chain reaction (PCR) are indicated in the third column.
 The genotyping of these microsatellite markers was based on automatic sequencer technology using fluorescent primers. Briefly, after amplification, the fluorescent polymerase chain reaction (PCR) products were loaded onto a polyacrylamide gel on an automatic sequencer according to the manufacturer's recommendations (Perkin Elmer). The size of the alleles for each individual was deduced using the Genescan® and Genotyper® software. The data were then kept on an integrated computer base containing the genealogical, phenotypic and genetic data. They were then used for the genetic linkage analyses.
 Several quality controls were carried out throughout the genotyping procedure:  independent double reading of the genotyping data,  use of a standard DNA as an internal control for each electrophoretic migration,  control of the size range for each allele observed,  search for mendelian transmission errors,  calculation of the genetic distance between markers (CRIMAP program) and comparison of this distance with the data from the literature,  further typing of the markers for which recombination between close markers was observed.
 The genotyping data were analyzed by multipoint non-parametric genetic linkage methods (GENEHUNTER program version 1.3). The informativeness of the marker system was greater than 80% for the region studied. The test maximum (NPL=3.33; P=0.0004) was obtained for the markers D16S541, D16S3117, D16S770 and D16S416 (FIG. 2).
 The typing data for these 26 polymorphism markers were also analyzed so as to search for a transmission disequilibrium. Two groups of 108 and 76 families with one or more sick individuals suffering from CD were studied. The statistical test for transmission disequilibrium has been described by Spielman et al. (1993). In this study, only one sick individual per family was taken into account, and the value of p was corrected by the number of alleles tested for each marker studied.
 A transmission disequilibrium was observed for alleles 4 and 5 (size 205 and 207 base pairs, respectively) of the marker D16S3136 (p=0.05 and p=0.01, respectively).
 These results, which suggest an association between the marker D16S3136 and CD, led to the construction of a physical map of the genetic region centered on D16S3136 and to establishment of the sequence of a large genomic DNA segment (BAC) containing this polymorphic site. It was then possible to identify and analyze a larger number of polymorphism markers in the region of D16S3136, and also to define and study the transcribed sequences present in the region.
Physical Mapping of the IBD1 Region
 A contig of genomic DNA fragments, centered on the markers D16S3136, D16S3117, D16S770 and D16S416, was generated from the human genomic DNA libraries of the Jean Dausset foundation/CEPH. The chromosomal DNA segments were identified based on certain polymorphism markers used in fine genetic mapping (D16S411, D16S416, D16S541, D16S770, D16S2623, D16S3035, D16S3117 and D16S3136). For each marker, a bacterial artificial chromosome (BAC) library was screened by PCR so as to search for clones containing the marker sequence. Depending on whether or not the sequences tested were present on the BAC clones, it was then possible to organize the clones among one another using the Segmap software version 3.35.
 It was possible to establish, for the BACs, a continuous organization (contig) covering the genetic region of interest, according to a method known to those skilled in the art (Rouquier et al., 1994; Kim et al., 1996; Asakawa et at., 1997). To do this, the ends of the BACs identified were sequenced and these new sequence data were then used to repeatedly screen the BAC libraries. At each screening, the BAC contig then progressed by a step until a continuum of overlapping clones was obtained. The size of each BAC contributing to the contig was deduced from its migration profile on a pulsed field agarose gel.
 A BAC contig containing 101 BACs and extending over an overall distance of more than 2.5 Mb, with an average redundancy of 5.5 BACs at each point of the contig, was thus constructed. The average size of the BACs is 136 kb.
Sequencing of BAC hb87b10
 The BAC of this contig containing the polymorphism marker D16S3136 (called hb87b10), the size of which was 163761 bp, was sequenced according to the "shotgun" method. Briefly, the BAC DNA was fragmented by sonication. The DNA fragments thus generated were subjected to agarose gel electrophoresis and those with a size greater than 1.5 kb were eluted in order to be analyzed. These fragments were then cloned into the m13 phage, which was itself introduced into bacteria made competent, by electroporation. After culturing, the DNA of the clones was recovered and sequenced by automatic sequencing methods using fluorescent primers of the m13 vector on an automatic sequencer.
 1526 different sequences with an average size of 600 bp were generated, which were organized with respect to one another using the Polyphredphrap® software, resulting in a sequence contig covering the entire BAC. The sequence thus generated had an average redundancy of 5.5 genomic equivalents. The rare (n=5) sequence gaps not represented in the m13 clone library were filled by generating specific PCR primers, on either side of these gaps, and analyzing the PCR product derived from the genomic DNA of a healthy individual.
 Sequence homologies with sequences available in public genetic databases (Genbank) were sought. No known gene could be identified in this region of 163 kb. Several ESTs were positioned, suggesting that unknown genes were contained in this sequence. These ESTs derived from the public genetic databases (Genbank, GDB, Unigene, dbEST) bore the following references: AI167910, A1011720, Rn24957, Mm30219, hs132289, AA236306, hs87296, AA055131, hs151708, AA417809, AA417810, hs61309, hs116424, HUMGS01037, AA835524, hs105242, SHGC17274, hs146128, hs122983, hs87280 and hs135201. The search for putative exons using the GRAIL computer program made it possible to identify several potential exons, polyadenylation sites and promoter sequences.
Transmission Disequilibrium Studies
 12 biallelic polymorphism markers (SNPs) were identified in a region extending over approximately 250 kb and centered on the BAC hb87b10. These polymorphisms were generated by analyzing the sequence of ten or so independent sick individuals suffering from CD. The sequencing was mostly carried out at known ESTs positioned on the BAC or in the region thereof. Putative exons, predicted by the GRAIL computer program, were also analyzed. The characteristics of the polymorphic markers thus identified are given in table 2.
TABLE-US-00002 TABLE 2 Characteristics of biallelic polymorphism markers studied in the region of IBD1 I II III IV V VI 1 KIAA0849ex9 AS-PCR SEQ ID No. 88 to 90 116 2 hb27G11F PCR- BsrI SEQ ID No. 86, 87 185 RFLP 116 69 3 Ctg22Ex1 PCR- RsaI SEQ ID No. 84, 85 381 RFLP 313 69 4 SNP1 AS-PCR SEQ ID No. 81 to 83 410 5 ctg2931- LO SEQ ID No. 78 to 80 51 3ac/ola 49 6 ctg2931- LO SEQ ID No. 75 to 77 44 5ag/ola 42 7 SNP3-2931 AS-PCR SEQ ID No. 72 to 74 245 8 Ctg25Ex1 PCR- BsteII SEQ ID No. 70, 71 207 RFLP 122 85 9 CTG35ExA AS-PCR SEQ ID No. 67 to 69 333 10 ctg35ExC AS-PCR SEQ ID No. 64 to 66 198 11 D16S3136 SEQ ID No. 37, 38 12 hb133D1f PCR- TaqI SEQ ID No. 62, 63 369 RFLP 295 74 13 D16S3035 SEQ ID No. 35, 36 14 ADCY7int7 AS-PCR SEQ ID No. 59 to 61 140 AS-PCR: allele-specific PCR; LO: ligation of oligonucleotides
 The 12 biallelic polymorphism markers newly described in this study are listed in this table. For each one of them, the following are indicated:  the locus (column I)  the name (column II)  the genotyping technique used (column III)  the restriction enzyme possibly used (column IV)  the oligonucleotide primers used for the polymerase chain reaction or for the ligation (column V)  the size of the products expected during typing (column VI)
 199 families comprising 1 or more sick individuals suffering from CD were typed for these 12 polymorphism markers and also for the markers D16S3035 and D16S3136 located on the BAC hb87b10. The families comprising sick individuals suffering from UC were not taken into account. The methods for typing the polymorphisms studied were variable depending on the type of polymorphism, using:  the PCR-RFLP technique (amplification followed by enzymatic digestion of the PCR product) when the polymorphism was located on an enzymatic restriction site.  PCR with primers specific for the polymorphic site: differential amplification of two alleles using primers specific for each allele.  Oligoligation test: differential ligation using oligonucleotides specific for each allele, followed by polyacrylamide gel electrophoresis.
 The typing data were then analyzed using a transmission disequilibrium test (TDT computer program of the GENEHUNTER software version 2). For the families comprising several affected relatives, a single sufferer was taken into account for the analysis. In fact, if several related sufferers are taken into account, this poses the problem of nonindependence of the data in the statistical calculations and can induce an inflation of the value of the test. The sufferer used for the analysis was drawn by lots, within each family, using an automatic randomization procedure. Given this randomization, the value of the statistical test obtained represented only one possible sample derived from the group of families studied. So as not to limit the analysis to this one possible sample, and in order to understand more clearly the soundness of the results obtained, for each test, about one hundred random samples were thus generated and analyzed.
 The markers were studied separately and then grouped according to their order on the chromosomal segment (KIAA0849ex9 (locus 1), hb27G11F (locus 2), Ctg22Ex1 (locus 3), SNP1 (locus 4), ctg2931-3ac/ola (locus 5), ctg2931-5ag/ola (locus 6), SNP3-2931 (locus 7), Ctg25Ex1 (locus 8), CTG35ExA (locus 9), ctg35ExC (locus 10), d16s3136 (locus 11), hb133D1f (locus 12), D16S3035 (locus 13), ADCY7int7 (locus 14)) (table 2). The haplotypes comprising 2, 3 and 4 consecutive markers were thus analyzed still using the same strategy (100 random samples, taking a single affected individual for each family).
 For each sample tested, only the genotypes (or haplotypes) carried by at least 10 parental chromosomes were taken into account. On average, 250 different tests were thus carried out for each sample. It was then possible to deduce the number of tests expected to be positive for each significance threshold and to compare this distribution to the distribution observed. For the healthy individuals, the distribution of the tests is not different from that expected on a random basis (χ2=2.85, ddl=4, p=0.58). For the sick individuals, on the other hand, there is an excess of positive tests, reflecting the existence of a transmission disequilibrium in the region studied.
 The results of the transmission disequilibrium test for each polymorphism marker taken separately or for the haplotypes showing the strongest transmission disequilibriums showed that the following markers and the disease are in linkage disequilibrium: Ctg22Ex1 (locus 3), SNP1 (locus 4), ctg2931-5ag/ola (locus 6), SNP3-2931 (locus 7), Ctg25Ex1 (locus 8) and ctg35ExC (locus 10). These markers extend over a region of approximately 50 kb (positions 74736 to 124285 on the sequence of hb87b10).
 The haplotypes the most strongly associated with Crohn's disease themselves also extend over this region. Thus, for the majority of the random samples, the transmission test was positive (p<0.01) for haplotypes combining the following markers:  locus 5-6, locus 6-7, locus 7-8, locus 8-9, locus 9-10, locus 10-11  locus 5-6-7, locus 6-7-8, locus 7-8-9, locus 8-9-10, locus 9-10-11  locus 5-6-7-8, locus 6-7-8-9, locus 7-8-9-10.
 The susceptibility haplotype most at risk is defined by the loci 7 to 10. This is the haplotype 1-2-1-2 (table 2).
 The markers tested are, as expected, in linkage disequilibrium with respect to one another.
 More recently, a new test, the Pedigree Disequilibrium Test (PDT), published in July 2000 (Martin et al., 2000), was used to understand more clearly the meaning of the results obtained with the TDT computer program. This new statistic in fact makes it possible to use all of the information available in a family, both from the sick individuals and from the healthy individuals, and to counterbalance the importance of each relative in an overall statistic for each family. The values of p corresponding to the PDT tests and obtained for an enlarged group of 235 families with one or more relatives suffering from Crohn's disease are given in table 3. This new analysis confirms that the region of the BAC hb87b10 is indeed associated with Crohn's disease.
TABLE-US-00003 TABLE 3 Results of the PDT tests carried out on 235 families suffering from Crohn's disease LOCUS VALUE p OF THE PDT TEST KIAA0849ex9 NS hb27g11f 0.05 ctg22ex1 0.01 SNP1 0.001 ctg2931-3ac/ola NS ctg2931-5ag/ola 0.0001 SNP3-2931 0.0001 ctg25ex1 0.0006 ctg35exA NS ctg35exC 0.00002 D16S3136 NS hb133d1f NS D16S3035 NS (NS: not significant)
Identification of the IBD1 Gene
 The published EST groups (Unigene references: Hs135201, Hs87280, Hs122983, Hs146128, H5105242, Hs116424, Hs61309, Hs151708, Hs87296 and Hs132289) present on the BAC hb87b10 were studied in the search for a more complete complementary DNA (cDNA) sequence. For IBD1prox, the clones available in public libraries were sequenced and the sequences were organized with respect to one another. For IBD1, a peripheral blood complementary DNA library (Stratagene human blood cDNA lambda zapexpress ref 938202) was screened with the PCR products generated from known ESTs according to the methods proposed by the manufacturer. The sequence of the cDNAs thus identified was then used for further screening of the cDNA library, and so on, until the presented cDNA was obtained.
 The EST hs135201 (UniGene) made it possible to identify a cDNA not appearing on the available genetic databases (Genbank). It therefore corresponds to a new human gene. Comparison of the sequence of the cDNA and of the genomic DNA showed that this gene consists of 11 exons and 10 introns. An additional exon, positioned 5' to the cDNA identified, is predicted by analysis of the sequence with the Grail program. These exons are very homologous to the first exons of the CARD4/NOD1 gene. Taking into consideration all of the exons identified and the putative additional exon, this new gene appears to have a genomic structure very close to that of CARD4/NOD1. Moreover, a transcription initiation site appears upstream of the first putative exon. For all of these reasons, the putative exon was considered to contribute to this new gene. The cDNA reproduced in the annex (SEQ ID No. 1) therefore comprises all of the identified sequence plus the sequence predicted by the computer modeling, the complementary DNA beginning randomly at the first ATG codon of the predicted coding sequence. On this basis, the gene would therefore comprise 12 exons and 11 introns. The intron-exon structure of the gene is reported on SEQ ID No. 3.
 The protein sequence deduced from the nucleotide sequence comprises 1041 amino acids (SEQ ID No. 2). This sequence has not been found on the biological databases either (Genpept, pir, swissprot).
 Now, more recently, it has not been possible to confirm the putative exon described above. The IBD1 gene therefore effectively comprises only 11 exons and 10 introns and encodes a protein of 1013 amino acids (i.e. 28 amino acids less than initially determined).
 The study of the deduced protein sequence shows that this gene contains three different functional domains (FIG. 3):  A CARD domain (Caspase Recruitment Domain) known to be involved in the interaction between proteins regulating apoptosis and activation of the NFkappa B pathway. The CARD domain makes it possible to classify this new protein in the CARD protein family, the most longstanding members of which are CED4, APAF1 and RICK.  An NBD domain (Nucleotide-Binding Domain) comprising an ATP-recognition site and a magnesium-binding site. The protein should therefore very probably have kinase activity.  An LRR domain (Leucine-Rich Domain) presumed to participate in the interaction between proteins, by analogy with other described protein domains.
 Moreover, the LRR domain of the protein makes it possible to affiliate the protein to a family of proteins involved in intracellular signaling and present both in plants and in animals.
 Comparison of this new gene with previously identified genes available in the public databases shows that this gene is very homologous to CARD4/NOD1 (Bertin et al., 1999; Inohara et al., 1999). This homology relates to the sequence of the complementary DNA, the intron-exon structure of the gene and the protein sequence. The sequence identity of the two complementary DNAs is 58%. A similarity is also observed at the level of the intron-exon structure. The sequence homology at the protein level is of the order of 40%.
 The similarity between this new gene and CARD4/NOD1 suggests that, like CARD4/NOD1, the IBD1 protein is involved in the regulation of apoptosis and of the activation of NF-kappa B (Bertin et al., 1999; Inohara et al., 1999). The regulation of cellular apoptosis and activation of NF-kappa B are intracellular signaling pathways which are essential in immune reactions. Specifically, these signal translation pathways are the effector pathways of the proteins of the TNF (Tumor Necrosis Factor) receptor family involved in cell-cell interactions and the cellular response to the various mediators of inflammation (cytokines). The new gene therefore appears to be potentially important in the inflammatory reaction in general.
 Several bodies of proof support bacteria-induced deregulation of NF-kB in Crohn's disease. First of all, spontaneous susceptibility to IBD in mice has been associated with mutations in Tlr4, a molecule known to bind to LPS via its LRR domain (Poltorak et al., 1998 and Sundberg et al., 1994) and to be a member of the activators of the NF-kB family. Second, treatment with antibiotics causes a provisional improvement in patients suffering from CD, giving credit to the hypothesis that enteric bacteria may play an etiological role in Crohn's disease (McKay, 1999). Third, NF-kB plays a pivotal role in inflammatory bowel diseases and is activated in lamina propria mononuclear cells in Crohn's disease (Schreiber et al., 1998). Fourth, the treatment of Crohn's disease is based on the use of sulfasalazine and glucocorticoids, which are both known to be NF-kB inhibitors (Auphan et al., 1995 and Wahl et al., 1998).
 Even more recently, it has been shown that the IBD1 candidate gene encodes a protein very similar to NOD2, a member of the CED4/APAF1 superfamily (Ogura et al., 2000). The nucleotide and protein sequences of IBD1 and NOD2 in reality only diverge for a small portion right at the start of the two reported sequences. The tissue expressions of Nod2 and IBD1 can, in addition, be superimposed. These two genes (proteins) can therefore be considered to be identical. It has been demonstrated that the LRR domain of Nod2 has binding activity for bacterial lipopolysaccharides (LPS) (Inohara et al., 2000) and that deletion thereof stimulates the NFkB pathway. This result confirms the data of the invention.
 The tissue expression of IBD1 was then studied by Northern blotting. A 4.5 kb transcript is visible in most human tissues. The size of the transcript is in accordance with the size predicted by the cDNA. The 4.5 kb transcript appears to be very poorly abundant in the small intestine and the colon. It is, on the other hand, very strongly expressed in white blood cells. This is in agreement with clinical data on transplants which suggest that Crohn's disease is potentially a disease associated with circulating immune cells. In fact, bowel transplantation does not prevent recurrence on the transplant in Crohn's disease, whereas bone marrow transplantation appears to have a beneficial effect on the progression of the disease.
 Certain data also call to mind alternative splicing, which may prove to be an important element in the possibility of generating mutants which may play a role in the development of inflammatory diseases.
 The promoter of the IBD1 gene has not currently been identified with precision. It is, however, reasonable to think, by analogy with a very large number of genes, that this promoter lies, at least partly, immediately upstream of the gene, in the 5' portion thereof. This genetic region contains transcribed sequences, as witnessed by the presence of ESTs (HUMGS01037, AA835524, hs.105242, SHGC17274, hs.146128, hs.122983, hs.87280). The ATCC clones containing these sequences were sequenced and analyzed in the laboratory, making it possible to demonstrate an exon and intron organization with possible alternative splicings. These data suggest the existence of another gene (named IBD1prox due to its proximity to IBD1). The partial sequence of the complementary DNA of IBD1prox is reported (SEQ ID No. 4), as is its intron-exon structure, on SEQ ID No. 6.
 Translation of the cDNAs corresponding to IBD1prox results in a protein containing a homeobox. Analysis of several cDNAs of the gene suggests, however, the existence of alternative splicings. IBD1prox, according to one of the possible alternative splicings, corresponds to the anonymous EST HUMGS01037, the RNA of which is expressed more strongly in differentiated leukocytic lines than in undifferentiated lines.
 Thus, it is possible that this gene may have a role in inflammation and cell differentiation. It may therefore also, itself, be considered to be a good candidate for susceptibility to IBD. The association between CD and the polymorphism ctg35ExC located on the coding sequence of IBD1prox supports this hypothesis even though this polymorphism does not cause any sequence variation at the protein level.
 Finally, more recently, the existence of a genetic linkage in families suffering from Crohn's disease and not comprising any mutation in the IBD1 gene also, itself, suggests that IBD1prox has a role in addition to IBD1 in genetic predisposition to the disease.
 The functional relationship between IBD1 and IBD1prox is not currently established. However, the considerable proximity between the two genes may reflect an interaction between them. In this case, the "head-to-tail" location of these genes suggests that they may have common or interdependent methods of regulation.
Identification of IBD1 Gene Mutations in Inflammatory Diseases
 In order to confirm the role of IBD1 in inflammatory diseases, the coding sequence and the intron-exon junctions of the gene were sequenced from exon 2 to exon 12 inclusive, in 70 independent individuals, namely: 50 sick individuals suffering from CD, 10 sick individuals suffering from UC, 1 sick individual suffering from Blau's syndrome and 9 healthy controls. The sick individuals studied were mostly familial forms of the disease and were often carriers of the susceptibility haplotype defined by the transmission disequilibrium studies. The healthy controls were of Caucasian origin.
 It was thus possible to identify 24 sequence variants on this group of 70 unrelated individuals (table 3).
 The nomenclature of the mutations reported refers to the initial sequence of the protein comprising 1 041 amino acids. The more recently proposed nomenclature is easily deduced by removing 28 amino acids from the initial sequence, and therefore corresponds to a protein comprising 1 013 amino acids (cf. example 5).
TABLE-US-00004 TABLE 4 Mutations observed in the IBD1 gene Nucleotide Protein Crohn's Ulcerative Health Exon variant variant disease colitis controls 1 Not tested 2 G417A Silent 2 C537G Silent 3 None 4 T805C S269P 48/100 6/20 3/18 4 A869G N290S 0 0 1/18 4 C905T A302V 1/100 0 0 4 C1283T P428L 1/100 0 0 4 C1284A Silent 4 C1287T Silent 4 T1380C Silent 4 T1764G Silent 4 G1837A A613T 1/100 0 0 4 C2107T R703W 10/10 1/20 1/18 4 C2110T R704C 4/10 1/20 0 5 G2365A R792Q 1/100 0 0 5 G2370A V794M 0 1/20 0 5 G2530A E844K 1/10 0 0 6 A2558G N853S 1/100 0 0 6 A2590G M864V 1/100 0 0 7 None 8 G2725C G909R 7/100 0 0 8 C2756A A919D 1/100 0 0 9 G2866A V9561 2/100 1/20 3/18 10 C2928T Silent 11 3022insC Stop 20/100 0 0 12 none
 The mutations other than silent mutations observed in each exon are reported. They are indicated by the variation in the peptide chain. For each mutation and for each phenotype studied, the number of times where the mutation is observed, related to the number of chromosomes tested, is indicated.
 No functional sequence variant was identified in exons 1 to 3 (corresponding to the CARD domain of the protein). Exons 7 and 12 did not show any sequence variation either. Certain variants corresponded to polymorphisms already identified and typed for transmission disequilibrium studies, namely:  Snp3-2931: nucleotide variant T805C, protein variant S269P  ctg2931-5ag/ola: nucleotide variant T1380C (silent)  ctg2931-3ac/ola: nucleotide variant T1746G (silent)  SNP1: nucleotide variant C2107T, protein variant R703W.
 Several sequence variations were silent (G417A, C537G, C1284A, C1287T, T1380C, T1764G and C2928T) and did not lead to any modification of the protein sequence. They were not studied further here.
 For the 16 non-silent sequence variations, protein sequence variants were observed in 43/50 CD versus 5/9 healthy controls, and 6/10 UC. The existence of one or more sequence variation(s) appeared to be associated with the CD phenotype. Several sequence variations often existed in the same individual suffering from CD, suggesting a sometimes recessive effect of the gene for CD. On the other hand, no composite heterozygote or homozygote was observed among the patients suffering from UC or among the healthy controls.
 Some non-silent variants were present both in the sick individuals suffering from UC or from CD and in the healthy individuals. They were the variants S269P, N290S, R703W and V956I located in exons 2, 4 and 9. Further information therefore appears to be necessary before selecting a possible functional role for these sequence variants.
 V956I is a conservative sequence variation (aliphatic amino acids).
 The sequence variant S269P corresponds to a variation in amino acid class (hydroxylated to immuno acid) at the beginning of the nucleotide-binding domain. This sequence variant and CD are in transmission disequilibrium. It is in fact the polymorphism Snp3 (cf. above).
 R703W results in a modification of the amino acid class (aromatic instead of basic). This modification occurs in the intermediate region between the NBD and LRR domains, which is a region conserved between IBD1 and CARD4/NOD1. A functional role may therefore be suspected for this polymorphism. This sequence variation (corresponding to the polymorphic site Snpl) is transmitted to sick individuals suffering from CD more often than at random (cf. above), confirming that this polymorphism is associated with CD. It is possible that the presence of this mutant in healthy individuals reflects incomplete penetration of the mutation as is expected for complex genetic diseases such as chronic inflammatory bowel diseases.
 The variant R704C, located immediately next to R703W, could be identified in both CD and UC. It also, itself, corresponds to a nonconservative variation of the protein (sulfur-containing amino acid instead of basic amino acid) on the same protein region, suggesting a functional effect for R704C which is as important as that for R703W.
 Other sequence variations are specific for CD, for UC or for Blau's syndrome.
 Some sequence variations are, on the contrary, rare, present in one or a few sick individuals (A613T, R704C, E844K, N853S, M864V, A919D). They are always variations leading to nonconservative modifications of the protein in leucine-rich domains, at positions which are important within these domains. These various elements suggest that these variations have a functional role.
 Two sequence variations (G909R and L1008P*) are found in quite a large number of Crohn's diseases (respectively 7/50 and 16/50) whereas they are not detected in the controls or in the individuals suffering from UC.
 The deletion/insertion of a guanosine at codon 1008 results in transformation of the third leucine of the alpha helix of the last LRR to proline followed by a STOP codon (L1008P*). This sequence variation therefore leads to an important modification of the protein: decrease in size of the protein (protein having a truncated LRR domain) and modification of a very conserved amino acid (leucine). This sequence modification is associated with CD, as witnessed by a transmission disequilibrium study in 16 families carrying the mutation (P=0.008).
 The mutation G909R occurs on the last amino acid of the sixth LRR motif. It replaces an aliphatic amino acid with a basic amino acid. This variation is potentially important given the usually neutral or polar nature of the amino acids in the terminal position of the leucine-rich motifs (both for IBD1 and for NOD1/CARD4) and the conserved nature of this amino acid on the IBD1 and NOD1/CARD4 proteins.
 In Blau's syndrome, the sick individuals (n=2) of the family studied carried a specific sequence variation (L470F) located in exon 4 and corresponding to the NBD domain of the protein. In this series, this sequence variant was specific for Blau's syndrome.
 In UC, several sequence variants not found in healthy individuals were also identified. The proportion of sick individuals carrying a mutation was smaller than for CD, as expected given the less strongly established linkage between IBD1 and UC, and the supposedly less genetic nature of the latter disease. Sequence variations were common to CD and to UC (R703W, R704C). Others, on the other hand, appeared to be specific for UC (V794M). This observation makes it possible to confirm that CD and UC are diseases which, at least partly, share the same genetic predisposition. It lays down the foundations of a nosological classification for IBDs.
 The study of the sequence variants of the IBD1 gene has therefore made it possible to identify several variants having a very probable functional effect (for example: truncated protein) and associated with Crohn's disease, with UC and with Blau's syndrome.
 The promoter of the gene is not currently determined. In all probability, however, it is likely to be located in the 5' region upstream of the gene. According to this hypothesis, the sequence variants observed in this region may have a functional effect. This may explain the very strong association between CD and certain polymorphic loci, such as ctg35ExC or Ctg25Ex1.
 The invention thus provides the first description of mutations in the family of genes containing a CARD domain in humans. The frequency of these mutations in various inflammatory diseases shows that the IBD1 gene has an essential role in normal and pathological inflammatory processes. This invention provides new paths of understanding and of research in the field of the physiopathology of normal and pathological inflammatory processes. As a result, it makes it possible to envision the development of new pharmaceutical molecules which regulate the effector pathways controlled by IBD1 and which are useful in the treatment of inflammatory diseases and in the regulation of inflammatory processes in general.
Bases for a Biological Diagnosis of Susceptibility to Crohn's Disease
 More recently, 457 independent patients suffering from Crohn's disease, 159 independent patients suffering from ulcerative colitis and 103 healthy controls were studied in the search for mutations. This study made it possible to confirm the mutations previously reported and to identify additional mutations, reported in FIG. 4. The main mutations were then genotyped in 235 families suffering from Crohn's disease. This more recent study is reported using, as reference, the shorter protein sequence (1 013 amino acids, see example 5), but the prior nomenclature for the mutations is easily deduced from the latter by adding 28 to the number indicating the position of the amino acids.
 Among the 5 most common mutations, the conservative mutation V928I (formerly V956I) is not significantly associated with one or the other of the inflammatory bowel diseases, and does not therefore appear to have an important role in the disease.
 The mutation S241P (formerly S269P) is in linkage disequilibrium with the other main mutations and does not appear to play an important role, by itself, in susceptibility to inflammatory bowel diseases (data not shown).
 Conversely, the other 3 mutations, R675W (formerly R703W), G881R (formerly G909R) and 980fs (formerly L1008P*), are significantly associated with Crohn's disease but not with ulcerative colitis (cf. below). The location in the LRR, or in its immediate proximity, of the 3 common mutations pleads very strongly in favor of a functional mechanism involving this protein domain, probably via a defect in negative regulation of NFkB by the mutated protein. The other mutations are more rare (FIG. 4). These cumulative mutations are present in 17% of the individuals suffering from Crohn's disease versus, respectively, 4% and 5% of the healthy individuals or individuals suffering from ulcerative colitis. A large number of rare mutations are also located in the LRR.
 The intrafamily studies of the three polymorphisms most common in Crohn's disease show that all three are associated with the disease (table 5). As expected, for a mutation supposed to be very deleterious, the polymorphism most strongly associated is the truncating mutation. These three polymorphisms are independently associated with Crohn's disease, since it was not possible to identify, on 235 families, chromosomes carrying more than one of these three mutations. The independent nature of these associations considerably supports the hypothesis that the IBD1 gene is clearly involved in genetic predisposition to Crohn's disease.
TABLE-US-00005 TABLE 5 Study of the 3 common polymorphisms of IBD1 in 235 families suffering from Crohn's disease MUTATION VALUE p OF THE PDT TEST R675W 0.001 G881R 0.003 980fs 0.000006
 The case-control studies confirm this association (table 6). They show that the mutations most common in Crohn's disease are not common in ulcerative colitis.
TABLE-US-00006 TABLE 6 Case-control study of the 3 common polymorphisms of IBD1 in inflammatory bowel diseases No. OF FREQUENCY OF FREQUENCY OF FREQUENCY OF TOTAL CHROMOSOMES THE ALLELE AT THE ALLELE AT THE ALLELE AT ALLELES MUTATION STUDIED RISK R675W RISK G881R RISK 980fs AT RISK Healthy 206 0.04 0.01 0.02 0.07 controls Ulcerative 318 0.03 0.00 0.01 0.05 colitis Crohn's 936 0.11 0.06 0.12 0.29 disease
 The study of the dose-effect of these mutations shows that individuals carrying a mutation in the homozygous or composite heterozygous state exhibit a much greater risk of developing the disease than individuals who are not carrying or are heterozygous for these mutations (table 7).
TABLE-US-00007 TABLE 7 Relative and absolute risk of Crohn's disease attributable as a function of the genotype of IBD1 In the general population, a risk of Crohn's disease of 0.001 has been taken as a reference, and it has been presumed that the mutations are in Hardy-Weinberg equilibrium. Distribution GENOTYPE SIMPLE COMPOSITE No HETERO- HOMO- HETERO- VARIANT ZYGOTE ZYGOTE ZYGOTE Healthy 88 15 0 0 Ulcerative 145 13 1 0 colitis Crohn's 267 133 28 40 disease Attributable risk of CD: Relative risk 1 3 38 44 Absolute risk 0.0007 0.002 0.03 0.03
 The studies mentioned above confirm the prior preliminary data and provide the detailed bases for a biological diagnosis of Crohn's disease by studying the IBD1 variants. In fact, this work:  1) defines the mutations, the frequency of which is greater than 0.001 in a mixed Caucasian population;  2) defines the frequency of the mutations observed and makes it possible to define 3 main mutations associated with Crohn's disease. Thus, it is possible, by virtue of this work, to define a strategy for studying the gene in order to search for morbid variants, namely: firstly, typing the 3 main mutations; secondly, searching for mutations in the last 7 exons; thirdly, searching for other sequence variants;  3) defines the practical modalities for searching for these mutations by pointing out their position and their nature. In fact, it is then easy for those skilled in the art to develop typing and sequencing methods according to their personal expertise. Mention may in particular be made of the possibility of genotyping the three main mutations by PCR followed by enzymatic digestion and electrophoresis, study of the migration profiles by dHPLC, DGGE or SSCP, oligoligation, microsequencing, etc.;  4) demonstrates the independence of the most common mutations which are not observed on the same chromosome in this extended and varied population. This information makes it possible to reliably classify the individuals who are composite heterozygotes (having two mutations) as carriers with a double dose of intragenic variations;  5) demonstrates that the great majority of the mutations only lead to a null or minimal effect on the risk of ulcerative colitis. This result makes it possible to envision assisting the clinician in the differential diagnosis between these two diseases. In fact, in approximately 10% of cases, inflammatory bowel diseases remain unclassified despite biological, radiological and endoscopic examination;  6) defines a relative and absolute risk of disease for the most common genotypes. This result lays down the foundations of a predictive diagnosis potentially useful in an approach of preventive monitoring and intervention in populations at risk, in particular the relatives of sick individuals;  7) demonstrates the existence of a dose-effect for the IBD1 gene and confirms the partly recessive nature of genetic predisposition to Crohn's disease. It therefore makes it possible to lay the foundations for genetic counseling and for intra-familial preclinical diagnosis.
 Finally, it should be noted that an additional mutation of the NBD domain was isolated in a second family carrying Blau's syndrome. The rareness of the two events in 2 different families is sufficient to confirm the involvement of this gene in Blau's syndrome and in granulomatous diseases in general.
 All of these data provide a diagnostic tool which is directly applicable and of use to the practitioner in his or her daily practice.
 The IBD1prox gene, located in the promoter region of IBD1, and the partial sequence of which is disclosed in the present invention, may also, itself, have an important role in the regulation of cellular apoptosis and of the inflammatory process, as suggested by its differential expression in mature cells of the immune system. The strong association reported in this work between the polymorphism marker ctg35ExC (located in the transcribed region of the gene) and Crohn's disease also pleads very strongly in favor of this hypothesis.
 Inflammatory bowel diseases are complex genetic diseases for which, until now, no susceptibility gene had been identified with certainty. The invention has made it possible to identify the first gene for susceptibility to Crohn's disease, using a positional cloning (or reverse genetics) approach. This is the first genetic location obtained using such an approach for a complex genetic disease, which demonstrates its usefulness and its feasibility, at least in certain cases in complex genetic diseases.
 The present invention also relates to a purified or isolated nucleic acid, characterized in that it encodes a polypeptide possessing a continuous fragment of at least 200 amino acids of a protein chosen from SEQ ID No. 2 and SEQ ID No. 5.
 Auphan et al. (1995), Science 270, 286-90.  Asakawa et al. (1997), Gene, 191, 69.  Becker et al. (1998), Proc. Natl. Acad. Sci. USA, 95, 9979.  Bertin et al. (1999), J. Biol. Chem., 274, 12955.  Buckholz (1993), Curr. Op. Biotechnology 4, 538.  Carter, (1993), Curr. Op. Biotechnology 3, 533.  Cho et al. (1998), Proc. Natl. Acad. Sci. USA, 95, 7502.  Duck et al. (1990), Biotechniques, 9, 142.  Edwards and Aruffo (1993), Curr. Op. Biotechnology, 4, 558.  Epstein (1992), Medecine/Sciences, 8, 902.  Guatelli et al. (1990), Proc. Natl. Acad. Sci. USA 87: 1874.  Hugot et al. (1996), Nature, 379, 821.  Inohara et al. (1999), J. Biol. Chem., 274, 14560.  Inohara et al. (2000), J. Biol. Chem.  Kievitis et al. (1991), J. Virol. Methods, 35, 273.  Kim et al. (1996), Genomics, 34, 213.  Kohler and Milstein (1975), Nature, 256, 495.  Kwoh et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 1173.  Landegren et al. (1988), Science 241, 1077.  Lander and Kruglyak (1995), Nat. Genet., 11, 241.  Luckow (1993), Curr. Op. Biotechnology 4, 564.  Martin et al. (2000), Am. J. Hum. Genet. 67: 146-54.  Matthews et al. (1988), Anal. Biochem., 169, 1-25.  McKay (1999), Gastroenterol. 13, 509-516.  Miele et al. (1983), J. Mol. Biol., 171, 281.  Neddleman and Wunsch (1970), J. Mol. Biol. 48: 443.  Ogura et al. (2000), J. Biol. Chem.  Olins and Lee (1993), Curr. Op. Biotechnology 4: 520.  Perricaudet et al. (1992), La Recherche 23: 471.  Pearson and Lipman (1988), Proc. Natl. Acad. Sci. USA 85: 2444.  Poltorak et al. (1998), Sciences 282, 2085-8.  Rioux et al. (1998), Gastroenterology, 115: 1062.  Rohlmann et al. (1996), Nature Biotech. 14: 1562.  Rolfs, A. et al. (1991), Berlin: Springer-Verlag.  Rouquier et al. (1994), Anal. Biochem. 217, 205.  Sambrook et al. (1989), Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Lab., Cold Spring Harbor, N.Y..  Satsangi et al. (1996), Nat. Genet., 14: 199.  Schreiber et al. (1998), Gut 42, 477-84.  Segev (1992), Kessler C. Springer Verlag, Berlin, N.Y., 197-205.  Smith and Waterman (1981) Ad. App. Math. 2: 482.  Steward and Yound (1984), Solid phase peptides synthesis, Pierce Chem. Company, Rockford, 111, 2nd ed. (1984).  Spielman et al. (1993), Am. J. Hum. Genet., 52, 506.  Sundberg et al. (1994), Gastroenterology, 107, 1726-35.  Temin (1986), Retrovirus vectors for gene transfer. In Kucherlapati R., ed. Gene Transfer, New York, Plenum Press, 149-187.  Tromp et al. (1996), Am. J. Hum. Genet., 59: 1097.  Wahl et al. (1998), B. J. Olin. Invest. 101, 1163-74.  Walker (1992), Nucleic Acids Res. 20: 1691.
9014374DNAHomo sapiensIBD1 cDNA 1atg gag aag aga agg ggt cta acc att gag tgc tgg ggc ccc caa agt 48Met Glu Lys Arg Arg Gly Leu Thr Ile Glu Cys Trp Gly Pro Gln Ser 1 5 10 15 ccc tca ctg acc ttg ttc tcc tcc cca ggt tgt gaa atg tgc tcg cag 96Pro Ser Leu Thr Leu Phe Ser Ser Pro Gly Cys Glu Met Cys Ser Gln 20 25 30 gag gct ttt cag gca cag agg agc cag ctg gtc gag ctg ctg gtc tca 144Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser 35 40 45 ggg tcc ctg gaa ggc ttc gag agt gtc ctg gac tgg ctg ctg tcc tgg 192Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp 50 55 60 gag gtc ctc tcc tgg gag gac tac gag ggc ttc cac ctc ctg ggc cag 240Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln 65 70 75 80cct ctc tcc cac ttg gcc agg cgc ctt ctg gac acc gtc tgg aat aag 288Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys 85 90 95 ggt act tgg gcc tgt cag aag ctc atc gcg gct gcc caa gaa gcc cag 336Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln 100 105 110 gcc gac agc cag tcc ccc aag ctg cat ggc tgc tgg gac ccc cac tcg 384Ala Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser 115 120 125 ctc cac cca gcc cga gac ctg cag agt cac cgg cca gcc att gtc agg 432Leu His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg 130 135 140 agg ctc cac agc cat gtg gag aac atg ctg gac ctg gca tgg gag cgg 480Arg Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg145 150 155 160ggt ttc gtc agc cag tat gaa tgt gat gaa atc agg ttg ccg atc ttc 528Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe 165 170 175 aca ccg tcc cag agg gca aga agg ctg ctt gat ctt gcc acg gtg aaa 576Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys 180 185 190 gcg aat gga ttg gct gcc ttc ctt cta caa cat gtt cag gaa tta cca 624Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro 195 200 205 gtc cca ttg gcc ctg cct ttg gaa gct gcc aca tgc aag aag tat atg 672Val Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met 210 215 220 gcc aag ctg agg acc acg gtg tct gct cag tct cgc ttc ctc agt acc 720Ala Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr225 230 235 240tat gat gga gca gag acg ctc tgc ctg gag gac ata tac aca gag aat 768Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn 245 250 255 gtc ctg gag gtc tgg gca gat gtg ggc atg gct gga tcc ccg cag aag 816Val Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Ser Pro Gln Lys 260 265 270 agc cca gcc acc ctg ggc ctg gag gag ctc ttc agc acc cct ggc cac 864Ser Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His 275 280 285 ctc aat gac gat gcg gac act gtg ctg gtg gtg ggt gag gcg ggc agt 912Leu Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser 290 295 300 ggc aag agc acg ctc ctg cag cgg ctg cac ttg ctg tgg gct gca ggg 960Gly Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly305 310 315 320caa gac ttc cag gaa ttt ctc ttt gtc ttc cca ttc agc tgc cgg cag 1008Gln Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln 325 330 335 ctg cag tgc atg gcc aaa cca ctc tct gtg cgg act cta ctc ttt gag 1056Leu Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu 340 345 350 cac tgc tgt tgg cct gat gtt ggt caa gaa gac atc ttc cag tta ctc 1104His Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu 355 360 365 ctt gac cac cct gac cgt gtc ctg tta acc ttt gat ggc ttt gac gag 1152Leu Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu 370 375 380 ttc aag ttc agg ttc acg gat cgt gaa cgc cac tgc tcc ccg acc gac 1200Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp385 390 395 400ccc acc tct gtc cag acc ctg ctc ttc aac ctt ctg cag ggc aac ctg 1248Pro Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu 405 410 415 ctg aag aat gcc cgc aag gtg gtg acc agc cgt ccg gcc gct gtg tcg 1296Leu Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser 420 425 430 gcg ttc ctc agg aag tac atc cgc acc gag ttc aac ctc aag ggc ttc 1344Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe 435 440 445 tct gaa cag ggc atc gag ctg tac ctg agg aag cgt cat cat gag ccc 1392Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro 450 455 460 ggg gtg gcg gac cgc ctc atc cgc ctg ctc caa gag acc tca gcc ctg 1440Gly Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu465 470 475 480cac ggt ttg tgc cac ctg cct gtc ttc tca tgg atg gtg tcc aaa tgc 1488His Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys 485 490 495 cac cag gaa ctg ttg ctg cag gag ggg ggg tcc cca aag acc act aca 1536His Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr 500 505 510 gat atg tac ctg ctg att ctg cag cat ttt ctg ctg cat gcc acc ccc 1584Asp Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro 515 520 525 cca gac tca gct tcc caa ggt ctg gga ccc agt ctt ctt cgg ggc cgc 1632Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg 530 535 540 ctc ccc acc ctc ctg cac ctg ggc aga ctg gct ctg tgg ggc ctg ggc 1680Leu Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly545 550 555 560atg tgc tgc tac gtg ttc tca gcc cag cag ctc cag gca gca cag gtc 1728Met Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val 565 570 575 agc cct gat gac att tct ctt ggc ttc ctg gtg cgt gcc aaa ggt gtc 1776Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val 580 585 590 gtg cca ggg agt acg gcg ccc ctg gaa ttc ctt cac atc act ttc cag 1824Val Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln 595 600 605 tgc ttc ttt gcc gcg ttc tac ctg gca ctc agt gct gat gtg cca cca 1872Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro 610 615 620 gct ttg ctc aga cac ctc ttc aat tgt ggc agg cca ggc aac tca cca 1920Ala Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro625 630 635 640atg gcc agg ctc ctg ccc acg atg tgc atc cag gcc tcg gag gga aag 1968Met Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys 645 650 655 gac agc agc gtg gca gct ttg ctg cag aag gcc gag ccg cac aac ctt 2016Asp Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu 660 665 670 cag atc aca gca gcc ttc ctg gca ggg ctg ttg tcc cgg gag cac tgg 2064Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp 675 680 685 ggc ctg ctg gct gag tgc cag aca tct gag aag gcc ctg ctc cgg cgc 2112Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg 690 695 700 cag gcc tgt gcc cgc tgg tgt ctg gcc cgc agc ctc cgc aag cac ttc 2160Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe705 710 715 720cac tcc atc ccg cca gct gca ccg ggt gag gcc aag agc gtg cat gcc 2208His Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala 725 730 735 atg ccc ggg ttc atc tgg ctc atc cgg agc ctg tac gag atg cag gag 2256Met Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu 740 745 750 gag cgg ctg gct cgg aag gct gca cgt ggc ctg aat gtt ggg cac ctc 2304Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu 755 760 765 aag ttg aca ttt tgc agt gtg ggc ccc act gag tgt gct gcc ctg gcc 2352Lys Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala 770 775 780 ttt gtg ctg cag cac ctt cgg cgg ccc gtg gcc ctg cag ctg gac tac 2400Phe Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr785 790 795 800aac tct gtg ggt gac att ggc gtg gag cag ctg ctg cct tgc ctt ggt 2448Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly 805 810 815 gtc tgc aag gct ctg tat ttg cgc gat aac aat atc tca gac cga ggc 2496Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly 820 825 830 atc tgc aag ctc att gaa tgt gct ctt cac tgc gag caa ttg cag aag 2544Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys 835 840 845 tta gct cta ttc aac aac aaa ttg act gac ggc tgt gca cac tcc atg 2592Leu Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met 850 855 860 gct aag ctc ctt gca tgc agg cag aac ttc ttg gca ttg agg ctg ggg 2640Ala Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly865 870 875 880aat aac tac atc act gcc gcg gga gcc caa gtg ctg gcc gag ggg ctc 2688Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu 885 890 895 cga ggc aac acc tcc ttg cag ttc ctg gga ttc tgg ggc aac aga gtg 2736Arg Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val 900 905 910 ggt gac gag ggg gcc cag gcc ctg gct gaa gcc ttg ggt gat cac cag 2784Gly Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln 915 920 925 agc ttg agg tgg ctc agc ctg gtg ggg aac aac att ggc agt gtg ggt 2832Ser Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly 930 935 940 gcc caa gcc ttg gca ctg atg ctg gca aag aac gtc atg cta gaa gaa 2880Ala Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu945 950 955 960ctc tgc ctg gag gag aac cat ctc cag gat gaa ggt gta tgt tct ctc 2928Leu Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu 965 970 975 gca gaa gga ctg aag aaa aat tca agt ttg aaa atc ctg aag ttg tcc 2976Ala Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser 980 985 990 aat aac tgc atc acc tac cta ggg gca gaa gcc ctc ctg cag gcc ctt 3024Asn Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu 995 1000 1005 gaa agg aat gac acc atc ctg gaa gtc tgg ctc cga ggg aac act ttc 3072Glu Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe 1010 1015 1020 tct cta gag gag gtt gac aag ctc ggc tgc agg gac acc aga ctc ttg 3120Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu Leu1025 1030 1035 1040ctt tga agtctccggg aggatgttcg tctcagtttg tttgtgagca ggctgtgagt 3176Leu ttgggcccca gaggctgggt gacatgtgtt ggcagcctct tcaaaatgag ccctgtcctg 3236cctaaggctg aacttgtttt ctgggaacac cataggtcac ctttattctg gcagaggagg 3296gagcatcagt gccctccagg atagactttt cccaagccta cttttgccat tgacttcttc 3356ccaagattca atcccaggat gtacaaggac agcccctcct ccatagtatg ggactggcct 3416ctgctgatcc tcccaggctt ccgtgtgggt cagtggggcc catggatgtg cttgttaact 3476gagtgccttt tggtggagag gcccggccct ctcacaaaag accccttacc actgctctga 3536tgaagaggag tacacagaaa cataattcag gaagcagctt tccccatgtc tcgactcatc 3596catccaggcc attccccgtc tctggttcct cccctcctcc tggactcctg cacacgctcc 3656ttcctctgag gctgaaattc agaatattag tgacctcagc tttgatattt cacttacagc 3716acccccaacc ctggcaccca gggtgggaag ggctacacct tagcctgccc tcctttccgg 3776tgtttaagac atttttggaa ggggacacgt gacagccgtt tgttccccaa gacattctag 3836gtttgcaaga aaaatatgac cacactccag ctgggatcac atgtggactt ttatttccag 3896tgaaatcagt tactcttcag ttaagccttt ggaaacagct cgactttaaa aagctccaaa 3956tgcagcttta aaaaattaat ctgggccaga atttcaaacg gcctcactag gcttctggtt 4016gatgcctgtg aactgaactc tgacaacaga cttctgaaat agacccacaa gaggcagttc 4076catttcattt gtgccagaat gctttaggat gtacagttat ggattgaaag tttacaggaa 4136aaaaaattag gccgttcctt caaagcaaat gtcttcctgg attattcaaa atgatgtatg 4196ttgaagcctt tgtaaattgt cagatgctgt gcaaatgtta ttattttaaa cattatgatg 4256tgtgaaaact ggttaatatt tataggtcac tttgttttac tgtcttaagt ttatactctt 4316atagacaaca tggccgtgaa ctttatgctg taaataatca gaggggaata aactgttg 437421041PRTHomo sapiensIBD1 plus putative additional 5' exon 2Met Glu Lys Arg Arg Gly Leu Thr Ile Glu Cys Trp Gly Pro Gln Ser 1 5 10 15 Pro Ser Leu Thr Leu Phe Ser Ser Pro Gly Cys Glu Met Cys Ser Gln 20 25 30 Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu Leu Leu Val Ser 35 40 45 Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp Leu Leu Ser Trp 50 55 60 Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His Leu Leu Gly Gln 65 70 75 80 Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr Val Trp Asn Lys 85 90 95 Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala Ala Ala Gln Glu Ala Gln 100 105 110 Ala Asp Ser Gln Ser Pro Lys Leu His Gly Cys Trp Asp Pro His Ser 115 120 125 Leu His Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg 130 135 140 Arg Leu His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg 145 150 155 160 Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe 165 170 175 Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys 180 185 190 Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro 195 200 205 Val Pro Leu Ala Leu Pro Leu Glu Ala Ala Thr Cys Lys Lys Tyr Met 210 215 220 Ala Lys Leu Arg Thr Thr Val Ser Ala Gln Ser Arg Phe Leu Ser Thr 225 230 235 240 Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu Asp Ile Tyr Thr Glu Asn 245 250 255 Val Leu Glu Val Trp Ala Asp Val Gly Met Ala Gly Ser Pro Gln Lys 260 265 270 Ser Pro Ala Thr Leu Gly Leu Glu Glu Leu Phe Ser Thr Pro Gly His 275 280 285 Leu Asn Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser 290 295 300 Gly Lys Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly 305 310 315 320 Gln Asp Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln 325 330 335 Leu Gln Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu 340 345 350 His Cys Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu 355 360 365 Leu Asp His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu 370 375 380 Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp 385 390 395 400 Pro Thr Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu 405 410 415 Leu Lys Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser 420 425 430 Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe 435 440 445 Ser Glu Gln Gly Ile Glu
Leu Tyr Leu Arg Lys Arg His His Glu Pro 450 455 460 Gly Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu 465 470 475 480 His Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys 485 490 495 His Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr 500 505 510 Asp Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro 515 520 525 Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg 530 535 540 Leu Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly 545 550 555 560 Met Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val 565 570 575 Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys Gly Val 580 585 590 Val Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr Phe Gln 595 600 605 Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val Pro Pro 610 615 620 Ala Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn Ser Pro 625 630 635 640 Met Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu Gly Lys 645 650 655 Asp Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His Asn Leu 660 665 670 Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu His Trp 675 680 685 Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu Arg Arg 690 695 700 Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys His Phe 705 710 715 720 His Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val His Ala 725 730 735 Met Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu 740 745 750 Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly His Leu 755 760 765 Lys Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala Leu Ala 770 775 780 Phe Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu Asp Tyr 785 790 795 800 Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys Leu Gly 805 810 815 Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp Arg Gly 820 825 830 Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu Gln Lys 835 840 845 Leu Ala Leu Phe Asn Asn Lys Leu Thr Asp Gly Cys Ala His Ser Met 850 855 860 Ala Lys Leu Leu Ala Cys Arg Gln Asn Phe Leu Ala Leu Arg Leu Gly 865 870 875 880 Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln Val Leu Ala Glu Gly Leu 885 890 895 Arg Gly Asn Thr Ser Leu Gln Phe Leu Gly Phe Trp Gly Asn Arg Val 900 905 910 Gly Asp Glu Gly Ala Gln Ala Leu Ala Glu Ala Leu Gly Asp His Gln 915 920 925 Ser Leu Arg Trp Leu Ser Leu Val Gly Asn Asn Ile Gly Ser Val Gly 930 935 940 Ala Gln Ala Leu Ala Leu Met Leu Ala Lys Asn Val Met Leu Glu Glu 945 950 955 960 Leu Cys Leu Glu Glu Asn His Leu Gln Asp Glu Gly Val Cys Ser Leu 965 970 975 Ala Glu Gly Leu Lys Lys Asn Ser Ser Leu Lys Ile Leu Lys Leu Ser 980 985 990 Asn Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu 995 1000 1005 Glu Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe 1010 1015 1020 Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu Leu 1025 1030 1035 1040 Leu 337443DNAHomo sapiensIBD1 genomic sequence 3tcaccatata actggtattt aaagccacaa gagcaggtgg gctcatctag ggatggagtg 60atatggagaa gagaaggggt ctaaccattg agtgctgggg cccccagtgt taggaaccag 120ccaagaagac agaaagagtg aaaatcagag agttggggtg tcctggagga aatgaagaaa 180atgccccaaa gaggaaggag ggaacaaata tgaccaatgc ccctggcaga gcaagcaggc 240tgagggctga ggattgagca atgggaggtc actggtgaca gtttcactgg agctggatgg 300ggaactagag ggaatgggag gggatgggag gacttgggga cagcagtaca ggcaacagac 360aagggggcct gctgtaaagg gagcagataa atgggattgg agccaaatga agaaggggag 420tgtcaagaga gtgctttact tttacaatgg agaattagag tgcattgtgc actggtgggg 480ggatttgatc tcttagggag agaacagtgt tagggaggga gaatgcagga tagctggggg 540agggtggggg gcttggcccc agcagagact caggacactt gggaagttga gcttccctgg 600gcttcccctc ctctcctgtc tgcaaggggt cagtgggctg agatttcagc acttaagcaa 660agcatttgct cttggcccca gagaaaccgg gctggctgtg gtctcaggaa ggaaggaggt 720gtccaggctc aggcctgggc ctgggtttca gggagggccc acgtgggtca ccccttgacc 780ctctctttca gcaaggaagt gatcctttct ctacatgggc ctcaccttgg ggaggacaat 840ggtgtctttg aagttgtagt aactgaagta gagatcaaaa ggcaatgcag atagactgac 900agatttcgcc tgaagagggg aagcccgacc aggtaataaa ggagtaagag gaaggatgtt 960aaggacaatt ttaggaaaca gataatgagt gaatattttt tctctctctt tcccaattta 1020aactgaagca ggagaaactg aagctagaca taatgattaa cttcccaagc tggtgagctt 1080cctgagctgg ttagtgagaa cagcactaag gccaggttct cctccccaga tgtttaagat 1140gagacaggac aatgcctgct cagagacagg gcctggctga attggccctc aggattctct 1200ctgctctgag gtttctggaa gaaggccagg gcagaggtgt ggtgatgtag ctgctgggag 1260gacagagctc cgagtcacgt ggcttgggcg ggcctcccct tcctggtgtc cacagaagcc 1320caacgtcact agctggggtg tgtatggctc acacgtaggc caggctgccc taggcttggt 1380gtgcaaggga ggggccccta cttacttgtg gcctgtcccc tcgtgaatgt gtctcatgtc 1440cccagtgggg tttttcagtg agggtcatgg tctccaggat gcacaaggct ttgtgccaga 1500attgcttgga attgcctagt tctggaaggc tggttggcca actctggcct ccggcttttc 1560ctttgggaat ttcccttgaa ggtggggttg gtagacagat ccaggctcac cagtcctgtg 1620ccactgggct tttggcattc tgcacaaggc ctacccgcag atgccatgcc tgctccccca 1680gcctaatggg ctttgatggg ggaagagggt ggttcagcct ctcacgatga ggaggaaaga 1740gcaagtgtcc tcctcggaca ttctccgggt aagaggagca ggcattgtcc cgtcccagct 1800tgatcctcag ccttctttca tccttggccg cgacatgctc ccaggcctgg ggtcagatgg 1860ggagtgctga ctctgtttct gggctgtttt ctggggagaa tgggtcggcg ggtttttttc 1920cccaggacct gggcagggtc aatggtgggg gccgctgtcg catccttggc tggtgtttcc 1980acagctgaga accactccag ggccaagccc agagcttatt ctaccctttt ttgtcctctc 2040ttcccctgtc ctcggccacc ccaccctctt ggctcctctg cttagatgtg ggcacaagga 2100ggagaactcc ttggcctgag agaactacct tagatcctgg cttccagtgg cctctgcagg 2160ggggtacacc ctctctccca agcagccaga cacacaagta acctcattgc ctcagtttcc 2220ccatctgacc agcacagggc cccctgtgcc ccagcagcgt tctgagagat tggagctttc 2280tccttttgct taccttggct accgtatgag gacggataca gagtgttccc cccaccccca 2340gcccagggga tatttgattc atgaacattc cctcagtgtc tttgtggggg acaatgctgt 2400gccaggctca gggatgccag gacgagtaag acccaggctc ccacgtggcc caggcaggga 2460gagagacaca taaacaacca tcaggaaaga ggtaaaatcc ccaggccact tggcatctgc 2520tcccttgagt gtctgggaat gtccctgatt tataaaaaga agctgacggc cctctttgtt 2580gtccatgcct acaccctttc actttcgttt cttcggggca ctgcagcagc ccttgtccac 2640agaccccatg acaatcgcag aactgaccat gctgagagat tttcttggct gctcagggac 2700cctgccaggg cttgaagctc ctggagggtc acttgccctc aaattcccag aacgcacagc 2760aggtcactga tgatagcagt ggcagcagtc tgtgcacggt ggtttcgagg gcgtgggagg 2820gaggtgaggg ccctagggca agtgtgtgtg ggaagtgttg atgggggaca aggcaccaga 2880acgctcggaa acaacttagt ttgcaccgta atttttcact tcgcctagga caggaccttt 2940agagcaatat tctgagtcta ccccttggag tagcagtgtg caaaacacac agcacgggct 3000tggggccccc gtggggaacc caaatgtaag agttagagac atgcattccg gagtcataca 3060tggctcgtgt tgaaatcctg actctgcctg tctagctgtg acacatcgta caaatcactt 3120agcttcttgg tgcctcagtg tcttcctctg tagaatgggt agatcatagg cactacttca 3180gagtggctgg gagggttcag tgaattcctg caggagagca cttagaatgg cacttggtgt 3240gtagtttatg cttaattaat attagccgtt actgaaactg ctgtagcctg aatccagcca 3300gcatgaaaga gcccctctca ccctgcttcg aagagaatga attccctgat tgtttggaag 3360atctctctct ctctctctgt cttttttttt tttttttgag aaacggtctt gctctcttgc 3420ccaggctgga gcgcaatggt gccatcttgg ctcactgcaa cctctgcctc ccgggttcaa 3480gtgattctcc tgtctcagcc tcctgagtag ctgggattac aggcgctcgc caccacgcct 3540ggctaatttt tgtattttta gtagagacag cgtttcaccg tgttggccgg gctggtctag 3600cgctcctgat ctcaagtgac cttgggagat ctcttgctcc taatattacc tcaagccttt 3660ttaaacgttt taagccggag accaagcatg gatatgggag ttaggggtct tgatttaatt 3720cttggttgct tcaaactctg tggaaccttg aggtgtttct tgccttctct gggtctcaat 3780tttcacatct atatggtggg gagcttggat tgggtaatgt ctgaggctag aaccatggcc 3840aactcgggtt ctgctggggc tgacttgccc tggccttccc tgaccaccct gcatctggct 3900tctggagaag tccctcactg accttgttct cctccccagg ttgtgaaatg tgctcgcagg 3960aggcttttca ggcacagagg agccagctgg tcgagctgct ggtctcaggg tccctggaag 4020gcttcgagag tgtcctggac tggctgctgt cctgggaggt cctctcctgg gaggactacg 4080agggcttcca cctcctgggc cagcctctct cccacttggc caggcgcctt ctggacaccg 4140tctggaataa gggtacttgg gcctgtcaga agctcatcgc ggctgcccaa gaagcccagg 4200ccgacagcca gtcccccaag ctgcatggct gctgggaccc ccactcgctc cacccagccc 4260gagacctgca gagtcaccgg ccagccattg tcaggaggct ccacagccat gtggagaaca 4320tgctggacct ggcatgggag cggggtttcg tcagccagta tgaatgtgat gaaatcaggt 4380tgccgatctt cacaccgtcc cagagggtga ggcactcctg gtgtgcatca cagagttctc 4440aggaaagggg tgcttagtca ccaagactga tttgtcctca tgaagtcagc ctgtggggta 4500acttggtccg tgggatttcc cctaaaaagg tagccaggca ggtaaaattt gctcttgact 4560cttggcagga aacatacaac tctttctttc ttcttttctt ttctttttct cactctgtta 4620ccctggctag aatgcagtgg cacaatcata gctcactgta gccttgaatt cctgcgctca 4680agtgatcttc tggccttaga gtagctggga ctacggctgc tgtaccacca tgaacagcta 4740attttttttt tttcttttag agatggggtg ttgctatgtt gcccaggctg gtctccagct 4800cctggcttta agcaatcctc ccgccttggc ctcccaaact gttgggattg caggcatgag 4860ccactttgcc tggccaacag aacacttctg ccgagaggaa gtgtgtggtg gccaggaact 4920cagattctgg agccagaatg gtgcaggctc aaggtcaacc ctgtgtgatc tcaggcttcc 4980ctatggagcc tctccagcct cagtctccct tgtttcagtt tcctcatcta caaaacaatg 5040ttaatagtca aatggtgcct atcctataag gctcttggga ggattcagtg agttaatttg 5100agtaatgctt aggatagtgt ctattaccac tggctgctat ttattatttc tgttatgagt 5160gatactctgt acttgtacac ttttatttct gtctgtttta aattaacagc acaacagacc 5220ataacactgc agtatattga atttatttta taattaacat agcatattat aaactaatat 5280agcttaaatg tttatgtagg atttctgaca tgaaattgca ttagatcata gatgttcaga 5340gttggtatat aacagcccct gagaatgtag taactcagca gagaccagaa ggtcagagaa 5400atgaccactg agtatttttg aaactctttt gttttcttcc aaatagtgat tcttagggct 5460cctgagaggc agatggaaca atcattaaca ttccacttta taaatcggga agttgagacc 5520aaggaaagta gtttgaataa gctcacagta gttaatgagg gggccagtgc tggaccaatt 5580ggccagcact ggtcattgac ttattcatcc atcattcatt tattcagcca gaatctatta 5640ggtgcttcat acatatttgc ttaaagtttg ttgtgttcat agagctttgc acacggtagg 5700tactccataa acatttgttg atgaaataag tgagttactg aatgaatgat tgaattagaa 5760tgacactgca gtgttaaaat gggctgggtt ggggaacatt ttagtttttg tttttgtctg 5820ttttccaaaa atgtatgtgt tgttcacatg agtctggata accctagatt gagattgatg 5880acataaataa atttgtcttc aaggctgcac taaagctggc tcacatggct aggtatttac 5940agagcagaag tggtgcagtc ctctctgatt agttgcacgt acagaagaca tattcgttat 6000tggactgacc ttagtttctc ttataatttg ttaggggaat tgaatcagcc catctgagaa 6060gttacaagat tgtgtcttgt catctttaaa agttcagcaa tgtgatgtgg tacagatggt 6120ctgaggggtt tggagaaggt agcctagatc cctagggccc agagaagaca ggatgtgaac 6180agaggaagta catggattgg tgaagaaaag aaatgggata actcatgggt caaagaagaa 6240atcatgatgg aaatcagaaa atattcagaa ccatacaata atgagaatat tatttatcaa 6300aatctattgg atgcagctaa agcaggacat agggggaaat ttacaacctt aggtgcctag 6360attaggaaag aaggaaggca tttgtttatt tatttgttta tttatttatt tgagatgggg 6420gtctcactgt gtcacccagg ctgctggagt gcagtagcac gatcataaat cactgaagtc 6480tcgaacttct gggctgaagt gatcctcccg cctcagcctt ccaagtaggt gggacacagg 6540ctagcaccac cataccaggc taattttttt tttgtagaca cagggtcttg ctatgttgag 6600gtctcaaact cctgggctca agtaatcctc ctccctcggc ttcccaaagt gctgggatta 6660caggcatgag ccactgcgcc catctaaggc tgaattttaa tgagctaaga attcatctta 6720agaaagggct aaatagacag caaaagcaaa cattgaaggt tgggactgag ctgagtgggt 6780agcagggatg ggagacaaca gatctgagga gagcaggaga ttttgaaagg attgcactgc 6840ctgaggttta agcctttaga atccagctct ctctgagctc cctttgagct ctgacattct 6900gtgactctga tttggtggcc ttcccttagt ggccttactg atttcatttg gatggtgctt 6960gtggtatatc caaccaacat gtcttcccaa atggcctttt aatttcctat aaagaagtag 7020ttgtcattga ttgcaggtta gggacagaaa atgctgtgga atgaaacaaa atgcaagtta 7080aagaactaaa ttccaaaaat acccattgct actattgact gagtgaattc ctactgtgtg 7140ccagacactg tacccagtcc attccctgta ttgttttatt taagcctcac aagggtatag 7200tgtgactaca ctgtttctta acaatgaaga aactgcccaa atcgcccatc tgggaagcgg 7260cccagctaga atttgaatcc aggcctgttt tcctccagag cttgtgctat tctctgtctg 7320tcataaaatg tgggggcttt gtgtggtaaa cttgctcagt tgggcatagc agttgttagg 7380aaacctgagg ctggtaacac cagctgtaat accagctgtc cgtctgactc atgcaactgt 7440taaagttgat agggctgagg tgtcagactg agctctgaat tgcctgattc ctataacaat 7500attaacttaa acatttttta aattgggaaa tgcaccatgc atacagaaga gtgtgtatat 7560ttcatatgta tagtgtaaac tgttcccatc acccaggtta aaaaacagga tgttgccagt 7620acctggggcc ttctttaact gcaactgcta gaggtaaaca ctggcttgac ttttgtgtaa 7680atcatctctt tgcctttctt taatgtttta gcatctttta aaataaatcc ccaaataatg 7740tattgttcta ttttgaaaaa ctgagtagca agccaaaaat agctgtgtaa agaaaggtca 7800cttaaattag gctgggtgca gtggctcaag cctttaatcc cagtactttg ggaggctgag 7860gcaggtggat cacaaggtca ggagatcgag accatcctgg ccaacatgga gaaaccccgt 7920ctctactaaa aatacaaaaa attagccaag aatagtggca tgtgcctgta gtcccagcta 7980ctcgggaggc tgaggcagga gaatcgcttg aacccgggag gcagatgttg cagtgagctg 8040agatcgcact gcttgaaccc gggaggcaga ggttgcagtg agccaagatc gcaccactgc 8100actctagcct gggtcacaga gcaagactct gtctcaaaaa aaaaaaaaaa aaaaagaaag 8160gttactattg ccttttctta gatgaaggtt cccaaggcag ggaaagctaa gtggagtctc 8220agggacttgg tctggctttt ccttccctgg gaatttataa ggacctcttc tgggaagtca 8280gtcggcaatg ccatgaatga gtctggggaa atattgggct cattgcaact ggagggtctg 8340gtaggactga tgtgaattag gtgctgtgtc cggaggaaaa tggccagagg aagtgggctg 8400ctttgtacag tcagtggtaa agttgccaaa ggctattata gctcacagga atgggccaag 8460gctaaacact cctgtggagt gaaatgaatg tcctcagctg actgaggcag cgggagttga 8520gaagaaacga tattagttca tggtgaagac aagtcaaata tagataaagg ttagggtcag 8580gcttgcctgg acatctagga gataactgcc ctcaacttgt ttgaatcttg agtcactgct 8640ccattttgtt tgaactggtg gccatctact tatagtatac agccatcaac ctgagatttc 8700cctacatggt cttcctgcct tggtctcctg tatcctgaat cctatggcct cttcttccct 8760ggtttactac attttgctag accgtatcct ccagtcaatt ccttagaatg aatgtatgaa 8820agttaaaatt tctgaggtct cacatgtctt aaagttccct catactggat tgatagtttg 8880gctgggtata aaattctggg ctggccatca ttttccttca gaattttgat tgcattattc 8940cattatcctc tcttttcaat attgcttcta agaattccaa aacctttttt tttttttctt 9000tttgagacag tgtctcactc tgtcacccag gctggaatgc agtagtgtga tctcagctca 9060ctgcaacctc cacctcctgg gtttaagcga ttcttcttcc tcagcctcct gagcagctgg 9120gattacaggc acccaccacc acacccttta gtagagatgg ggttttgcta tgttggccag 9180gctggtcttg aacttctgac tttaggtgat ctgcctactt cggcctccca aagtgctggg 9240attaaaggcg tgagccacca cacccagcct ccaaaaccat tttaaaactc tttctggaag 9300cttttaaaat tttcttttag tccccagaat tttaaaattt caattatgtg ccttggtgtt 9360cttccattat attagtcacc caagaggtac tttcaatctg gaaacttctc tatgttttgg 9420gaaatgttct tgattagttt acaggtgatt tcttcctctc cattttatct cttctctttt 9480catgaaacta ctattaattc aatgttagaa ttccttgact gatcatttaa ttttcttcta 9540ttttccatct ctgtgtcttt ttgctctact tttctatgat agtcacagct ctatctttaa 9600actcttgagt ttttcatttt tgatgtcatg attttaattt gcaagaggta ggtttgactg 9660attctttttt gtagtatctt actcttgttt tatggatgca acatcttctt tgacttaagg 9720atcataagat aggtgggttc tttgtttgtt tgtttgactg tttttcaccc tatgtaaact 9780ttttctacaa gtttctttcc ccttcccccc tttttggctt ctatctccca cattagatgc 9840tttctctggg ctcatgatac tctttggttt tctttctcaa gattgacagg taggacttta 9900aaacttgttg agcatgcggg tgaaacttgt ctaccatgaa tttcactgta gatattttgg 9960agattgacag tgtttatatc tttagatctc acctcctggg ttgatcaagt tatctgagta 10020caccacagac cttttgcctg gggataaacc agaaatctgt ttcagaaacc actttgattc 10080agtcttcctt gttttagtca tttccttcag ttccggaggt ccgtcatgct gatcattcca 10140gagcccttta cagatcctag ggtacacact gcatggtttt caactttctt gttttggggt 10200taagatttgg ctttcaggag tctcctcagt ccgttactat tcattcaatc agcaagtcct 10260tgagcacctg atttgtgcca gacattcttc taggtgttag ggatacctca gtgaacaaaa 10320cagacaaaaa tctttgtctt ggaaatacac acactccagt caggggagag ggacaataag 10380ccaaaggaag gaaattacag cgtgtgctag aaggtgataa gtgctgtaga aagtaagtaa 10440agtgggtttg ggagttgaga gtttgggaag gggataaatg atggcaattg taaatagagt 10500agtcagagtt ctcacttaga aggtgaaatt caagtaaaga cttgaaggag gacagggaat 10560tagccacatg gatggctagg ggaaggcttc caagctgaga ggacagccag agccaaggcc 10620cagaggcagg agcatacctg gtagttttag gaaacaggag gccaggatgc tgagtggagt 10680aagagggggc atgaaaggag aaacttgggt ccacgtggtt ctagacaggt atttttgtct 10740gttttgggcc ctgaaggtta ctattggact tggactctta ctctgaggaa atagggacgc 10800tattgggacg tttgtacagg agcaatgtga cctgagtttt gtttgtaaag gattagactc 10860tggctgtggc attaaggcta ggctgtgggg gcaggaacag aagcaggggg accagttttg 10920cagcctgtgc agctttccag ataagcaggg attgtggctt ggaggaggat ggtatagagg 10980aggtgacaag aaatgactct atgtctggta tgtagatatt ggccacagat ggcatttgag
11040cactagagac ctggctggtc cacatggagt ttccataagc acataataca catcagattt 11100caaagactta atatgaaaaa aaaaatttaa cgggccccgg gaattttttt cttttttttt 11160ttttttgaga cccagtcttg ctctgtcacc caggctggag tgcagtggtg tgatctcggc 11220tcactgcaac ctccgcctcc caggttcaag tgattctcct gcctcagcct cctgagtacc 11280tgggactaca ggcacctgcc accacgcctg gctaattttt tgtattttta gtagtgatgg 11340ggtttcacca tgttgtccag gctggtctgg aactccggac cttaggggat ctacccgcct 11400tggcctccca aattgctggg attacaggca tgagccacca tgctcagcca tatcttgcta 11460ttttctacat ggattacatg ttgaaatggt aatgttttgg ctattgtgga ttaaatagaa 11520tatatgatta aagttgattt catctatttc ttttaacttt aaaaaatatg tctgttagag 11580gatttgaaat tccacatgcg gcttgcattt gtgacctgca tttcatttct gtggaacagt 11640gccctttttg ggacatgctt tgaaggtgga gtcaacagga tttggcagat tacagacgag 11700aggcttcaag ggtgactcca agacttcggg gcagagcacc tggaagaaag gggttaatat 11760tagccaagat gaggaaggct gtcggtttgg caggtgcatg ggcaggttag gagtttagtt 11820ttgaatatgt tggaggtgtt tatgaaactt ttaagtggag atggaaaata ggcagttgga 11880tgtgcaagtc cagggttcag ggagacagtt caggctggag atgaagatgt gggagtctga 11940ggagagattg tattcaaata ttcaatccat gagacttgat gaaatcactt ctcttccaaa 12000tgatttacag cctgcagaat cattttccct atctttgtag gtttatgtct tcattttgtt 12060tcatttattt ttcagttatt cactgtttta gtgagttttg agtaggagcc agattggatg 12120catgcgttca attcaccatc caacactgta ttaactactt gaaactcatg tggttgttcg 12180gttgtttttt tgacctttta ttctggatgg aagagagatg cttatgaagt tgcagtaatc 12240agtaagcctt cccacattgc tccatcagcc ttcctggaag aataatgtct tctgcctttc 12300ctgtaggcaa gaaggctgct tgatcttgcc acggtgaaag cgaatggatt ggctgccttc 12360cttctacaac atgttcagga attaccagtc ccattggccc tgcctttgga aggtaggtgt 12420atgttctcag ttaatcagaa agggaagggc agtcagtgca gatccatggt taagagcaga 12480acacacctcg gttaacatcc catatgctgg cagtatagcc tccctatgac tcaatttcct 12540tgttttaagg ctagcaccac cccgtctcat tgggattttg ggagcattaa aaggacaaaa 12600gcgtgtaatg ttagctatta gctttcatta tctcccacac agtatactga caattgggct 12660accatatatt gagggctaac taaaggtgtt acttaccatc caaactctca ttatctgtac 12720cgaaaagata tggacacatg ttttgagtta gggctggtat ctcttgatct ctgaaattta 12780gcagctcaca atgggaaact caagaaccaa gtggatctag agactctggt atccctcagt 12840gcccagggtc accacccaaa ctcaggaaca ggaggggctt ggaccgcacc acttgaacat 12900accaggcatc ctgccaggtg ctttatggac aatgtctacc ctttgcaaca accctgagaa 12960gtaggtggtg tttttttcca ccttatagat gtggaaactg ggcagggagg ttaagtgacg 13020agggagggga agatgggtct gattgtaaat tgtccccacc tacactttct cttttcttgg 13080gagaagaaat gtcagttgta aagagagagt gcaagcctgg cactctttag ggcttgttcc 13140tacaccactg tagggaaagc tcattggcac tgaagccccc tgagctgtgt gtggtgctgg 13200cagatgggtc tatcaccctg gactgtgtcc tctgggcagc aagcaagcct gtgggcgggg 13260tggctggaag tctgtgcctg gcactcgcga gtgcaccgtc tcattgaaga acaggatcta 13320aacatcagtg cgccacagca gggtgcgcgg cacggagtgc aggccctggt ttggcccttg 13380gttgaggttt gctgttgaca tcatcaagca cagctagtca ctgtaagacc aggccagggt 13440gcaagattcc ccacacttct aaaggtgaca attggtgtat ttatttctct ataaaatgac 13500attttttttt tctggagaat tttagtatca ttggtgatga ctggaaaacc tgcatcagaa 13560atcaggtcgg aagaggaaga tatatatctg atatgtactg gagaggaaga tatctatctt 13620atggtctaag ttcagggatc ctggtatatt cagagggcag aaagctcagc aataatcatc 13680aactctggga acagaggtga cataaacaca gggcgtcccc tttgtgtgac tgcagatagt 13740catcagtgag ctcagagctc tatgaaaatt acttgctagt ttttgggttg aaaatagtgg 13800gccagtgttt ggttgggggc agtgaggctg tgatggcggg ggaccatgcc aagctcctac 13860cagcctggga cgctaaacca gcacttcccc atttcctgaa aggggaacta aactctgaca 13920caggaaatgg tttgcttgca ttactttcag gatgagaaag gaagagcact ggccttccaa 13980acacaccccg tgcatgaaaa ctctccctgc atggggtgca tggggaggat ggggaagtgg 14040aggcaggatc acagactctt gttcgagtgc tcagctgggg caccccggtg accccgaggc 14100cttcccttgc taggtccacc cagatcaatc aggatcatct ccccatctcg aagtttaact 14160ttatcacatc tcagagttcc ttttgccacg taaggtaaca tattcacagg ttctgagaat 14220ccggacatgg acatctttga gggtctattg ttgtgcctac tatatccatg aataataatg 14280ataataagca ccattttttg agagtttgcc atgtcagata ttcttttaaa ctgtatttta 14340tctcgctgcc tcctgaaaaa atccttccag gtgtatattg tccccatttt tacagatgag 14400agaactgagg cccagaaagg ctaaatggct tgcccaagtg tatggtggac ccaggttttc 14460aaactcaggt gtgtctggct tcagagactg ggctcctgag cccttaagcc ctttgttccc 14520ctttagaaaa agtcacctga ggctgagtgg tgaagggatt tatccaaagc cacccggcca 14580ctatggcagg acagatatca gaatacaggt cttccgatcc cagcccagag ccccttcccg 14640tcatctagaa ctcctcctgg tgtcagtaat gataacggca gtcactgatg tcttttgagc 14700acttactttg tgttgagcac ttacactgtg ctaagcactt gacataggtc atcttagttg 14760atccgtgtaa aactctgtga ggtagtgacc aacatttctc ccaccttaca gaggtggaaa 14820ctgagggtta ggaagtttcc ttgactgtcc tcaaagtgca cagcttgtga atggaggagc 14880caggatgggc gcccgctggc tctcctatcc cttcagttat gtcagcgtcc cccgcagcag 14940cccattgtct ggttaggtcc cgtcttcacc atggtgccac cttcatctgc ctcttcttct 15000gccttccagc tgccacatgc aagaagtata tggccaagct gaggaccacg gtgtctgctc 15060agtctcgctt cctcagtacc tatgatggag cagagacgct ctgcctggag gacatataca 15120cagagaatgt cctggaggtc tgggcagatg tgggcatggc tggatccccg cagaagagcc 15180cagccaccct gggcctggag gagctcttca gcacccctgg ccacctcaat gacgatgcgg 15240acactgtgct ggtggtgggt gaggcgggca gtggcaagag cacgctcctg cagcggctgc 15300acttgctgtg ggctgcaggg caagacttcc aggaatttct ctttgtcttc ccattcagct 15360gccggcagct gcagtgcatg gccaaaccac tctctgtgcg gactctactc tttgagcact 15420gctgttggcc tgatgttggt caagaagaca tcttccagtt actccttgac caccctgacc 15480gtgtcctgtt aacctttgat ggctttgacg agttcaagtt caggttcacg gatcgtgaac 15540gccactgctc cccgaccgac cccacctctg tccagaccct gctcttcaac cttctgcagg 15600gcaacctgct gaagaatgcc cgcaaggtgg tgaccagccg tccggccgct gtgtcggcgt 15660tcctcaggaa gtacatccgc accgagttca acctcaaggg cttctctgaa cagggcatcg 15720agctgtacct gaggaagcgt catcatgagc ccggggtggc ggaccgcctc atccgcctgc 15780tccaagagac ctcagccctg cacggtttgt gccacctgcc tgtcttctca tggatggtgt 15840ccaaatgcca ccaggaactg ttgctgcagg agggggggtc cccaaagacc actacagata 15900tgtacctgct gattctgcag cattttctgc tgcatgccac ccccccagac tcagcttccc 15960aaggtctggg acccagtctt cttcggggcc gcctccccac cctcctgcac ctgggcagac 16020tggctctgtg gggcctgggc atgtgctgct acgtgttctc agcccagcag ctccaggcag 16080cacaggtcag ccctgatgac atttctcttg gcttcctggt gcgtgccaaa ggtgtcgtgc 16140cagggagtac ggcgcccctg gaattccttc acatcacttt ccagtgcttc tttgccgcgt 16200tctacctggc actcagtgct gatgtgccac cagctttgct cagacacctc ttcaattgtg 16260gcaggccagg caactcacca atggccaggc tcctgcccac gatgtgcatc caggcctcgg 16320agggaaagga cagcagcgtg gcagctttgc tgcagaaggc cgagccgcac aaccttcaga 16380tcacagcagc cttcctggca gggctgttgt cccgggagca ctggggcctg ctggctgagt 16440gccagacatc tgagaaggcc ctgctccggc gccaggcctg tgcccgctgg tgtctggccc 16500gcagcctccg caagcacttc cactccatcc cgccagctgc accgggtgag gccaagagcg 16560tgcatgccat gcccgggttc atctggctca tccggagcct gtacgagatg caggaggagc 16620ggctggctcg gaaggctgca cgtggcctga atgttgggca cctcaagttg acattttgca 16680gtgtgggccc cactgagtgt gctgccctgg cctttgtgct gcagcacctt cggcggcccg 16740tggccctgca gctggactac aactctgtgg gtgacattgg cgtggagcag ctgctgcctt 16800gccttggtgt ctgcaaggct ctgtagtgag tgttactggg cattgctgtt caggtatggg 16860ggagcaccat caaggctaag tgtgggagca ccgagctggg ctctagaagt ctgggcccag 16920cttcgcctct gccaccctgc tttgcaacac tgcccagatc ccttcccttc tgggccttaa 16980tttcaatatg tgatgatgac agccacactt tattgactgg cctatgtgct gggtctggtg 17040ctatgctttc cggaatgacc tcatctaatc tctacaacca ccctgggggg taggcaggaa 17100tgttattatc tccattatcc ttgacttgag gctcagagaa gtgaagtaac ttgtccagga 17160aatggcagag ctggggttca caaattgcat cattctgatt acaggttttc tgcctcccac 17220cagtctatgg atacacttca gaggctccct gaaaaccttg aggtcacttg cagaaagttt 17280tgtgtagtat gtgtccgtat caggaacaac accaaatcag aggtgacttg tgccccatca 17340gagactttaa caccccaacc agatgggaat ttcaggaccc aagaaataga aagtggctgc 17400agggttacaa ctactgttgg attcctgagg tagcacagtg tccaaacagg atttcagcac 17460tacccgtatt gcttagagcc ccagccaaag atgtgaggtt ttgccctttg gagaatctgt 17520gcccctgaac tcgggggcct ctttccacat cttgggggca ggcaagggca gagggtgtgc 17580ctaggcctgc ggatcagcat gcgacagatt ccccaacatc cttccagctt gaaaggggat 17640tgccctgctt ctatttagaa cctataggaa agcagaagtt ctagattgaa gttaaaattg 17700attcccagcc tccaggggct ttgggctaca cctggatgac cttaattgac cctaagcatg 17760ggacaaacca cttcctgaga gtattaggat ggtatacatc ttctctgggg gcaaagcaac 17820aagatttatt tttcatcatg gaccaaacac atggataccc actagaaact gtgtagtgaa 17880ttttgttaac cctgacatag ggaccatggt ctttaggtta aagcataata acaacataat 17940acataacata tatagcgaat atatatatgt attatatgca atgaatgtaa atatgattat 18000acccatcatg gtcttggagg aaacagatga cacacttaaa atgggtgttt tgaggagagt 18060ttgaaaaaca gattgtttac aagccatggg caggagttag gaagagtgag agggttggtg 18120caggggcctg gggttagtaa cagctggggg agggtagact tgaaggggga aggggaggga 18180gactaattag ctggggggaa ggtatggaga cggctgcctg agcttctgca aagtggaaga 18240atactgcttg gccctaactc ctcaccccaa ctcttgctcg tggccagcgc cttccaccag 18300ctggacccat cagggaggcc gagtgggctg tctgctggag tagtccccag gcatcagcct 18360cccaggagcc agggacgggt agagaagggg gagagtggat ctggccaggc aaatggaaaa 18420cagccagcac caaactctat ttccctagga gggaggatca tgatactttg agtgggaatt 18480tggaaacctg tctgttggag caatttccct gatagaaata agaatgtgca ttttcctggg 18540tagtagactc agtttttacc ccaagaggcc aggcatcact ggcctgtgtg atcctcatag 18600gccagtccat ctctggaatt cttgaatgga tcatccatcc ttgattaggg atgtccccgt 18660gattaccagg gtgtgcagaa gggctctggg aaacctgtgg gtctgtctct gtgttcagag 18720aaaggtgagg gtggcctggt tctagctcat ggtgctcaga ctgtggtgtg taaaggcact 18780cgtggcaatg cagattcctg ggcctgcctc tagtgattcc cattcagtag gtttggggtg 18840gggcccagga aatctatatt tttcacagac acccctggtg attctgatac aagtggtctc 18900gccctgggag aactactggt ctgcagcaac cagcttggtt ttccattagc aattactgtc 18960cttgagcgag ttttactgct cttcacctta cacacactaa aactgccaag gccgtagggg 19020aggggaagca accatgaggt tgctgtgagt gcactgtgtg tgtgtgtgtg tgtgtgtgtg 19080tgtgtgtgtg tgtatgagag agagagagag attgagaaag agaggaaggg aggaaggggg 19140agggcacagg ctcctctccc acagtgccaa cctgcctctc tcccacttga agcgtttcca 19200tgccaactga aatcctcagc ctctaggaaa ccctatatac acagtgcccc tatataggtt 19260tctttagact ctggctctct cagactctag agtgatggct ttaaaagttt tatgttaccc 19320acagagagag agcacgcacc accatgtaaa catggaacct aagtttcaca aaatgacttc 19380gctttatgaa ctctgagaca ctctgctctc ttctgttctg ttctatttcc attttagaaa 19440tgctgctcag gaccttcaaa atgatttgca tgacctgcaa cctgcagtct gaaaaatcac 19500tgcactacag aagtggccat aagaggccct gagggagaag ctgcacaatg tcatggttaa 19560gagtggggtt tggagccaag ccgcctaggc tcaaagcctt tatgtgccgt acaaccttgg 19620caaagtcact tcgcttgtct gtgcctcagt ttctttctca cgaatgctca taataatggt 19680tcccatttca ctggcttgtt gtgaggatga aatagtgtta ttattgagaa gtggtaaggg 19740tagtgatcag tgctagcgat catgattcta ggtgactttt actgtgtacc gggtgctcac 19800aaggctttat gtgcacagcc tggtgaggct gataatacta ttgttccctc tttttttttt 19860ttggaaacgg agtctcgttc tgttgcccag gctgggggta cagtggcaca atctcggctc 19920atgcaatctc tgcctcccgg gttcacgcca ttctcctgcc tcagcctccc aagtagctgg 19980gactacaggc gcctgccacc acgcccggct aatttttttg tatttttggt agcgacaggg 20040tttcactgtg ttaaccagga tggtctcgat ctcctgacct cgtgatccgc ccgcctcggc 20100ctcccaaagt gctgggatta caggcgtgag ccaccgtgcc cggcctgttc cctcttttat 20160agatgaagag accagcaaat aactagtaag tcgctgatca ggatcacaat atccagctga 20220ggcactccag agcctgagct gttaaccatt cagtcagggc ctcccaagtt tgcctaaaga 20280taaagaatca tgtgcacagt tgttaaaata tacagattcc tgggccccac cccgcagata 20340cttgattgcc agctccaggg tatgggcctg agaatctgtc ttttagggaa gctttcagat 20400gatgttgtga tcaggtgagt tttgggaatg gtgccccaag aggagtggca gacagggctt 20460gctcggcagg gactagcctg ttggagtggt gccattgggg ttaaggactg ggcagcaggg 20520cctcactaac cacagcctat atgcctgttt ctgaagtttt ggccactctc atccagctgg 20580tctactgtct gctgacctag atgatggtaa attgtcccca ggggtagcct gtctagttca 20640ggctgcacct ttcgcatata tcagctcctt tccaccatca tcccctttgt gaggctgctg 20700tgattatcat gttccttttg cagagatgga aacattgcct caaattagct ctgtcatttc 20760ctaaggattc cagggttctt tagtaggggg tctggatcct acgtcctggg ccatccccat 20820catagtgcac cacgtcacct ccctggccag ggaccgtggg gtctccactt ttttggggtg 20880ctccatctat gcagggtttc ctggaagcac agatgctggc acttcaggga tgaatgaaag 20940tctttttggg ggatttgtag atttttttct tgtcttacta gctccatttt caaatgtatt 21000tattttgtct ctttagtttg cgcgataaca atatctcaga ccgaggcatc tgcaagctca 21060ttgaatgtgc tcttcactgc gagcaattgc agaagttagc gtaagtcagc ctgggctgtg 21120gacaatgggc tccaagtgcc ctggtctcac cccaggtcgt gcagcctggg aagctgtgag 21180tgatgggctg gggcaggggc tgtttgcatg atggggggtg caggtgattc ctgcccagag 21240gggaagggca accctgggat ttggtgctca ctgtccaatg tgctttgctt ctgtgtctcc 21300tctcttctgg aactgaacag tctattcaac aacaaattga ctgacggctg tgcacactcc 21360atggctaagc tccttgcatg caggcagaac ttcttggcat tgaggtgagc ccaggttttc 21420cttattccct ggaaactatt ttttgcccca ttcctgagtc agtctgatct ggtcttggcc 21480tggcactgcc cacactggct cctgacctcc tgattgaatg cagggacagt gtctcatttt 21540aagcaggggt tctctaatgc tgtgatctcc ccagtaaact ctggactagc tctgctgagg 21600acttcctgtc ttttgacctt tagcccgtag ggcaagaaag cttttctagg cccctttcct 21660tttctgtgtc taagagtgtc acagctttct ggggttactg agttccacga tgcatgttga 21720gctcgtcctg gtgggggagg catacacagt tacttgccac cccagctgtg gcagcgagtt 21780gctgcaacac tcccaggagg tcctttcacc actcagagca tgcaaggttt gcagtccatc 21840tggttctgca tttctgctac tccagtgtct cccagtttca acaggagtct ctctctctcc 21900tacctgatgc ctttaaattg cccctctagc tggccgctgg gttggcctgg cttctctctc 21960cttctctctc tctcagatat tcttgcctcc tgtgatttgt gaggcagtaa aaaaagacaa 22020agtaaagaat tgcttccatc tattctttta cctcttgggc tgggtttgtg gatgggagcc 22080gccattttaa aatggcgggc cacatagctc agtctcggca agggctactg agatcagaac 22140cacaggtgcc aatttgtaca aaggactcag tcctgctacc actgcctgat ccctcagact 22200cacaagcctg gaataggctg tggccagacc tggctggccc atccctgaga agggtgctag 22260tttcagaaat ggaggctgag tttgtggcca acacagtagt cctccggtat gtgcaggaga 22320gatgttctaa gaccccagtg gatgcctgaa accatggaga gtatcaagcc ctacacatac 22380catgcttttc ccaataccta cacacctgca ataaagtgta gtttataaat taggctcagt 22440aagagagtaa tagcaactca taataaaata gaacaattat aacaatcaat atactataat 22500aacactatgt gaatgtggac tctctccatc tccctcaaaa tatcttcttg tactgtactc 22560acccttcttc ttgggaagat gtgtggtggt aaaatgcctg tgtgatggga ggaagtgagg 22620tggatgacgc atgcagcact gtgctctagc gctgggctgc tgttgacctg accacacttc 22680agaaggagaa tcatctgctc ccagagatcc ctaatctttg agcaacaatg aggtcggcag 22740ctggatgtca ggagcagacg atcttgatga ttaccaaatg ggagcgtata gagcgtggat 22800gcgctggacg gggggctgat tcacgtcctg ggtgggatgg agctggatgg cacgtgatca 22860gaatagcatg caatttaaaa tgtatgaatt gtttatctct agaattttcc atttaatatt 22920tttggactgc agttgatttc agataactga aaccatagaa ggcgaagctg cggataagca 22980gggggcaggg attaccgtat atcattgtaa tagagagcac aggctctgga gccagactgc 23040ccgaggtttg aaccctcatt agctgcgtga cctcaggtca gcccaatgtc tgtgtgcctc 23100cgtttcccct tctgtagaat ggaggtaata accctggcta cctcacaggc tgtagtgatg 23160agcaagcaag ttaatccaca tgaagggctg caccgtctgg caggggcttt atatagtaag 23220cgagtggctg aaagatgatg ggtaaatcac acaagcactc agcttgtttc tccttatgtg 23280agtccggtcc tccaagcagg gattcaatgt gccacccatt tattggggaa aagtcctaaa 23340aggggaagtg gggaagggag ctgggggagg ctgggaggtg tgtccctgag tgaaggagag 23400agggaaggaa ggaaggttga gactgggcac cttggacttc agtgcagtcc taagacatct 23460tggcaaggct gatgaggagt tcttgaacca aattcaccag gcaggggagc ctgatgtctc 23520aggcaggggc tggcaagtgc agatgcgagg atgttagatt ttggagcaca gcagctgggg 23580cccttggcta cctccaagga gctgaggctg gagacctgaa aggcgagttc tcctagctgc 23640cacacccctt ctccaaggat acaataatat ctgccttata ggattgttgt gagctgagtg 23700gcttgacgtt ccttgaaaga atgaaagcgt atagttatcc caggaagcct agggttgcag 23760gtgagagctc tggggcttct ccgaagctct ccgaggtgtc tggattcagt tgcagcagga 23820gccttccttg ctgggatctt cccccacccc tagccttggc cctccctctc tccttccttt 23880ctggaaggct cagtgggccc cacccctccc tccagccacc tggacctgcc cagcgctctt 23940gtgcaacagg taaagcctac ctgtagcaac aacagatctg ggaaggctgc agagggcacg 24000atggggtctg gatcgagggc ggctgagacc agagggaaag gtgtgaccct gagtcaccct 24060cgctgtcccg gggaaaccac ctcccaggac agctgcctac tgtggctcct gcctggaatt 24120gtcacactgc tgtgcaaaca gcgtcccgct gcccctttcc ctttgctggg ggaaaatgaa 24180gttgtgggag ccgctgagta aactagacct agcagcgagg gcacctgatg tggctgctgc 24240ctcccgggca ggtcttcaat gctttcttcc tgtgtttccc tggccagggc acagacggcc 24300ctccttttct gcctgccgct gtgttctctc agcctcctct gtcttccctt ccaggctggg 24360gaataactac atcactgccg cgggagccca agtgctggcc gaggggctcc gaggcaacac 24420ctccttgcag ttcctggggt aggttggatt ccaggaagag ggacctgcat ggaggggctt 24480gggacttttg aggatttagg ggcaggtgaa actcttcagc caggaggccc cagaggcagc 24540ccagctccag tggggaggac aagccaggga gagagtgggc ggcccttgac tgccaccttc 24600atacttggtc tatgcctgac aaacaggaag tttgggatgt tggggctagg ggaggacagt 24660gcccacgagc tggtgacagg aagccctctg atcctcaggg ggcgctaggg ctgtacttta 24720gctgcatatt aaaaccacct ggaagcttct aaacactatt gccaggcctc ccaccccaga 24780ctgatgaaat gcaaatatct aggtgcaagg cccaggtatc aggagtttta aaaagcttcc 24840caggggatgt acagccaggg gtgaggaccc ctgacctaag aaagagaagg aaatggggaa 24900ggataggaag gcacccagga taagaggggc tgtgctaggt ccctcggagc tcttgctccc 24960tgtaggacca tgctagggcc tgccagggag gggagtaccc caacctgcag ccccagggtg 25020ggcttcctct gtttgctagg cacccaggct tgcacctgtg ctgtttccag cagcctctct 25080cctatcctgt catgccctag tgtgaactgg agtccatttg acaagaactg ggagttttag 25140aacctgggac tgtaggaaga gagaataacc ttagggccta ggtgttccag cccatttcac 25200agggaggcaa gttgccccca agctcagttt tttgttttgt tttgttttgt ttgagatgta 25260gtctcactct gttgcccagg ctagagtgca gtggcacgat cttggctcac tgcaacctcc 25320gcctccttgg ttcaagcgat tcacctgcct cagcttctca agtagctggg attataggca 25380cccaccacca cgcccagcta atttttgtat ttttagtaga gacagggttt caccatgttg 25440gcccggctgg tcttgaactc ctgatctcag atgatccgcc cgcctcggcc tcccaaagtg 25500ctgggattac aggtgtgagc caccgcaccc ggcccccaag ctcagtttga gccacaaatg 25560ggactatgtt gctctagaaa tcaacatctt ttccacactg cattagtagc aacagagtct 25620agaacaaagg aggccacagc cccactgaac tctcttctgc ttgaggtcac atctgccaca 25680tcaggggtat ttacctcttt caacacatat ttattagggc acctgtctgg gccaggcgtt 25740gtgctaaaac ccccaaacgc tgtcatatga tacaaagtgt tctgtaactt gcttggtttt 25800tttttttgtt tgtttgtttg ttttgttttg tttttgttgt tgtttttttt tgcttcgcca 25860tatattatag gaattttttt aggtcattat gacctcttta tttacttaat tatctattta 25920tttattttac taatatttac agaaagggtc tcactctgtc acccaggctg gagtgcagtg 25980gttgcaatca tagctcattg tagccttgaa ctcctgagct caagtgatct tcctacctcg 26040gcctcctgag tagctgggac tacaggcaca agccaccatg cctggccgat atttttatgt
26100tttgtagaga cggggtctca ctatgttgcc caggctggtc tcaaactcct gggctcaggt 26160gatcctccct cctttgcctc ccaaagtatt gggattacac aagtgagcca ccttgctcag 26220cctgacctca tttttcaaag agctgcagag tgttacataa tgtatttaac tggtcacttt 26280ttgatgacta ttaagttgtt ttcaggtttt ttgttattac agtgtcatat ccctggggca 26340cagagcagtg ctggcacata gccagagctc aatcgataca tacctaatga atgaaagtac 26400agtggacatc ctaattcagc cattctttgc taacttgtgt acatacctgt ccagggtagg 26460tccctagaat acagtcaata agtcagaagg tgtgagttgg gatctacctt ttggaaaggg 26520atgttttcaa actacagtga gtcagaggag gatggcccag aagctggggg agttgaagct 26580gatggcgtga aggaattagg ggtgttagga agaagcagga gataaagagc tagcttgcag 26640aagaagtgtt agacttgtta tgggcaggta ctggagggta gctaaggact tgtgggtggc 26700agttaccagg aagcgtatct gaactaagtg tcagaaaaag tgtcacaact gtaaattact 26760cttgtcagtg agttcctgtc cttaagggtt agggctgggt agccctctac tattctctaa 26820gtctgtaatg taaagccact gaaaactctt gggttaagtt tggccatccc acccaaaaga 26880tggaggcagg tccactttgc tgggaccagg agccccagtg aggccactct gggattgagt 26940ggtcctgccc ctctggctgg gactgcagag ggaggaggac tgttagttca tgtctagaac 27000acatatcagg tactcactga cactgtctgt tgactctttt ggccttttca gattctgggg 27060caacagagtg ggtgacgagg gggcccaggc cctggctgaa gccttgggtg atcaccagag 27120cttgaggtgg ctcaggtaag cttcagagtc tatcctgcag ttttcttggg gagatcaggt 27180gaagagggag gagctggggc cagttctgaa ggtctttgaa ctttatttct accccacaat 27240gttaggcaat ggagtaagga aaaaagacca ttggatttca agagaggaca cttgagtctt 27300tctgggtgac ttggaaatgt cccttgtcct ctcagggttt tgatacagta tctgtaaatt 27360gaagatattg ggctggatca ggtacatttt atcttaaggg ccaattccaa tccattggta 27420gtgggtgccc agtgcaccac attaaaaaga attctaaggc tgcacctggg cttaaagaag 27480agcactataa tcaattagtg atgtctaaaa aagctaaaaa aaaaaaaaaa gagcactgca 27540ttcaattagt gatgtctaaa aagggtagaa aaaaaaaaaa aaagaaaaaa gaaagagcac 27600cgcaatcaat tagtgatgtc tgaaatggag cagaccagga gagcaccacg aattttgccc 27660tccataggtt agctcatctc tgaggtcttt ccctgctctg acatactttt gttccatgat 27720tacctccagc ctggtgggga acaacattgg cagtgtgggt gcccaagcct tggcactgat 27780gctggcaaag aacgtcatgc tagaagaact ctggtgagtt tgggggattc tctgctctgg 27840ggaagtggat cacaatctct gttgatcccc tggcctcatc cataggagcg gttgtgtgga 27900cagacaaagg tggatgattg agtgattgac tgattgattg attgtgtttg tctttatatg 27960tactgagtgg tatgaagctt atagagcctg gtatgtacat gctaattttt ttatttaata 28020aaatatatgg gtttgctggt ttggtgactg cctccacatg gcataagtgt taagagcaca 28080gactctgtaa tcaagcaggc cgtgatctta ggcaagttaa ataacaattt cagaatctca 28140agtttcatgt ctgtaaaatg agggtaagaa tacttccaac cataaaggat ttttgcaaga 28200attagataaa gtagtgcctg tgaagacctt aatatagtgc ctggcatatt tgtaagtgct 28260ccataaatgt taaattagaa taatggcagg gttactacta ctattactgc tgctgctgct 28320gctgctgctg ctacaactac tatagtactg tgactactac tactaataaa gttttgttat 28380tttaaagtga ttttgagttc ctaggagcac tgggtattca agtcttaggt cattttggaa 28440ggtgtaatgg agttttgata gttgaaagag gaaccatgaa tcatgcttat actgttgacc 28500tgaagcagat tctaagtttc tcatccttta gatgccacta gtatagtttt ctgacatgtt 28560ctgggcagct tcagattatg tcagggagat aaaatactga atgtttgatt ttcccgggaa 28620gcagaaaggc actgcaacat atgggcattg ccataaacag attttatgga tggaccttgg 28680ctgttgcagg gcttactagc tctactcaag tatgattgat tctatcctga ctggattttg 28740ccacttggaa tttcttagta gaggagaacc ttgttatgag agcatcagtt atgattactg 28800ttaaaagaaa aactttaggc aaattaaatt tagcagaact ggtttgaaca tacagcaatt 28860tatgaattgg gcagcattca gaactgggag tgctccaccc agcaaggtag gcaagcagta 28920tctatagaca ggaaaaggaa gtgatgtaca aaacagcttg attggttgca gctgggcatt 28980tgccttatat gggcatggtg tgatgaggca ttttctttat atggatatag actgatcagc 29040tggtagactg tgactgactg aagcctggct gctgtgattg gctaagactt agctgtttgt 29100tataaggata tgttgttagg ttgcagtttg ctacatagga actcaaagta cagaggcagt 29160ctcaggccaa atttagttta actatatgtt aagctgcagg tgacagaata cctccatcta 29220tagaggttta aacaaggaaa gggtttattt tttcctgtat aggcagctgg atgtaggcag 29280tgtagggttt gtacagtggc tacaagaggc caggaggggt ctcagctctg tctcattctc 29340ttcctgttcc atcatcctta gcctgtaact tcattcacat ggttggttgt ctcatgatca 29400caggatggct gctccaggtg cagcactact tctgtattcc cggattcgat ctatataccc 29460aggaaagcca tctgggttct ctcctttaaa aagcattcct ggaagcccca cctgtcgact 29520tccccttatg tatcaaccat gtgtatgtca cttgaccaac ccacttgtat gttgtttgac 29580cagccctggc tgcaatggag agtgggaaat acagtttttt caccaagtgc atggctgtcc 29640aaatgaaatg agacttccat taataaggaa gaaaggaaag atggagatca ggaagctggg 29700ggatcaggga acttattaca ttgagagccc ttggagtgaa ttctcttgca aatatgtccc 29760tggaattgag aatccccaca acgtctttat ctgttctttc tttatccatg agtttgggtt 29820ttcagatgtt ggatttccta tatggggggc atgtgagttc atcatcttcc ataatcaatg 29880ttgtatcaac tggattttct ctcttcttct caccagcctg gaggagaacc atctccagga 29940tgaaggtgta tgttctctcg cagaaggact gaagaaaaat tcaagtttga aaatcctgaa 30000gtaaggaacc cataagcagg aaacaggaca ataattgctg gcctttggaa ggggcatttc 30060tgattaagat ctgggccgct ctccgctggg ctaactcatg tgaggtggcc tggtagaaca 30120gcttgccttg gtctaggtgg acaaggattc cagtgcaagt tgtttatctg ggaggtggtc 30180ccagtaaatg ctgataggag agtggtgaag tgagatgggg aagtgaaggt aaccaataaa 30240ggggagttat caagccagtt atcaatgagg gaaattggag ctcagtactc tggggcactc 30300ctggagccag tgcagaacac acatggtcac ctacccaacc aatgggcaag aaagccatgg 30360catttatcca ccaaccctct gtccttccta tgttgatgtg cgctcatggg gcactgattc 30420tccagcactt ccagctcacc ctcacccagc tgaacatgct tctggggtca ggagaatggc 30480ctcaggcaga gagtggcagg tcttctctgc aagcagtggc tggggaggtg atgtgatggg 30540gagtactgtg gcctcctcca gtggctgact cagtggcttg ggacttgtgc cacaaagaga 30600tggacagctc aggtgaacat gaacccacct agtgaccatc atgggtttgt cagggtgctc 30660tctgaggctg atgccaaaat tcttatttca agtagacctc aggaacccca tcagatggct 30720ccttttgctg gaggaaagtg gcatctgcct aggcaaatgt ggtcctagga aaacgcttgc 30780ctttagagac agacagacag acagctgcct ctgtgagtgc cagctttgct gccaggctgc 30840tacccactct ggcgacactc atttgtgttg ctttcacaag ctaggaagtt tccaaatatt 30900tggagaaaac acttccacta attatttggg tggaaatggg ctgggaagtt ggggtgaagc 30960ccggatgtgt ctgagccaga tgccagcttt gcactgaggg tcggcctttg ggaataccaa 31020gcccattatc aaccaggtgt ggatatggca ggtttgtctt ccctccttgt cacagcctta 31080ctccacttga ctcccatgga tgccaggcaa tgaggctggg gttggtccca tgccaccctg 31140tcatcagcct tatttttcag catcctaaac tatatcatcc cccacaaaaa ttgaacttct 31200gatatatctt ttataaaaaa gagaaatgcc tacatctttc ttttccagga ttagtttctg 31260ccaagagttg gttgagagcc caggcttgct gggtgcagtg gctcacacct gtaatcccag 31320cactttggga ggctgaggcg ggtggatcac ctgaggtggg gagttccata ccagcctgac 31380caacatggag aaaccccatc tctactaaaa atacaaaatt agccgggcgt ggtggcatac 31440acctgtaatc ccatctactc aggaagctga ggcaggagaa tcacttgaac ctgggaggtg 31500gaggttgcca tgagccaaga tcacaccatt gcaccctaga ctggacaaga gagaaacttc 31560catctcaaaa aaaaaaaaaa ggatgagaaa aataataatt taaaaaaaag agtccaggct 31620ctggaaccag acagcctggg tcttacccct gctccaccat taccagccag ttcttcttgg 31680atgagtgcct cagttgcctc aagtgtaaat ggagataatg gctggacctt cattataggc 31740catgagcatt cactgagaga atgtagctaa caaaagtgag ttgtaggttg gagcaaaagt 31800aattgtggtt tcagaccatg aactttaaat tattataact aggctaaaat acatctttat 31860taatcaaaat aggaaccatt aaaatcaaca catttttgcc aataagaaat aagtttgttt 31920attcctgtag cataaaaatt catgcttcgg gattcaacaa actcttggaa agcattttct 31980gcatcctcct ggttgtggaa gcatttttcc tgcagaaagt tgtcaagatt cttgaagaaa 32040tggtagtcag ttggctagag gtcaggtaaa tatggcggat gaggcaaaac ttcatagtcc 32100aattcattca acttttgaag ctttggttgt gtgacatgca gtccggttgt tgtcgcggag 32160aattggaccc tttctgttga cgaatgccgg ttgcaggtgt tgcagttttc agtgcatctc 32220attgacttgc cgagcatact tctcatatgt aatggtttcg cagggattca gaaagctgta 32280ggggatcaga ctagcagcag accaccagtg accatgacct tttttttttg gtgcgaattt 32340gcctttggga agtgctttgg agcttcttct cggtccaacc actgagctag tcattgccag 32400ttgtataaaa tccacttttc atcgcacgtc acaatcagat caagaaatgg ttcgctgttg 32460ttgtgtagaa taagagaaga tgacacttca aaatgacgat tttcttggtt ttcactcagc 32520tcatgaggca cacacttatc gaggtttttc acctttccaa tttgcttcaa atgctgaatg 32580accatggaat ggtcgatgtt gagttctcaa gtagttgtaa gaaaatcagc tttgatgatt 32640gctctcaatt ggtcattgtc agcttctgat ggcctgccag tacactcctc atcttcaagg 32700ctcttatctc cttcgcaaaa cttcttgaac caccactgca ctatacgtta gttagcagtt 32760cctgggccaa atgcattgct gatgttgtga gttgtctccg ctgctttaca acccattttg 32820aattcaaata agaaaattgc ttgaatttgc tttttgtcta acatcatttt catagtctaa 32880aataaatata aaataaacag aaagtattaa gtcattagca aaaaatcata aagtgagaat 32940tgtgcattaa aatgatgtat agcataacca catttattta agaatgtatt ccaatatcaa 33000atggcaaatt tcaacaatgc aaaaactgca attacttttg caccaatcta atagaagttc 33060aataaatact ggcaattaca attggcattg ccttagggtc aacttgtaag acattcctga 33120aattgtggga aagggggagg acctggagtg gacattattg gaaggcaaag ctgtaaccaa 33180aagagcaacc tgggaaacac atgactcctc tgttgctgtc cctggcccta tcctgtctcc 33240cctccctgtt gtcagctacc tcatatgttc tctaatctct gtctctgtgc cctcaaagac 33300ccccctgaaa atagaaatat tactgctcat tggttatttt ctatcaatta agtactgtat 33360tagtccgttt tcatgctgat gataaagata tacccaagac tgggcacttt atgaaagaaa 33420gagttttatt gaacttacag ttccacgtgg ctggggaggt ctcacaatca tggctgaagg 33480tgaaaggcac atctcacatg gcagcagaca ggagaagagg gcttgttcag ggaaactccc 33540ctttttaaaa ccatcagata tcatgaaact tatttactgt aatgagaaca ggatgggatt 33600caattacctt ccactgggtc gctcccacaa cacgtgggaa ttcaagagat ttgggtgggg 33660acacagccaa accatatcaa gtactgtgca agtgttttag gcatgcagag agtggtgggt 33720cttcccagca agcagagtgt ggggaggtaa tgggggactg gtggctgact taatggccca 33780ggacccatgc cacaaggaga tggatggtgg atgtgaatag gagcctgctt acacccatca 33840caatttagat tcttatgctc gatggcacgg gtactctttt aggcccattt taccaatgag 33900gagattggga ctaatttgct cgagatcaaa aaagaagtgg tgtaggtggg atttaaaccc 33960aggatgtcta gcactaaaat gcaggtactt aaccactatc ctaagggagt ggctacttaa 34020tttgataaac tcatctagtg aatggaagag agacggttac atttcactga tggtactgag 34080cctttgttga tgagctcatt gggaatctca gacatgagca ggatgtgtct aagggacagg 34140tgggcttcag tagactggct aactcctgca gtctctttaa ctggacagtt tcaagaggaa 34200aaccaagaat ccttgaagct caccattgta tcttcttttc caggttgtcc aataactgca 34260tcacctacct aggggcagaa gccctcctgc aggcccttga aaggaatgac accatcctgg 34320aagtctggta aggcccctgg gcaggcctgt tttagctctc cgaacctcag tttttctatc 34380tgtaaaatgg ggtgacggga gagaggaatg gcagaatttt gaggatccct tctgattctg 34440acattcagtg agaatgattc tgcatgtgaa ggatctgatt ctctgtctaa gaaagaagtc 34500tttacctctt taagtaggga gcaatgattt catttttaaa ccttgactat ttattcagca 34560acttctctgc tctatgagat agtgtaggaa tggggatgtg gttgaagaat gaaaagaaaa 34620gtcagctccc gccctcctag aaattgcatc tgccttcaca ggtcaaggat attggatcag 34680accttctgcg gttctgaatg gagattacac aggttaggag caggttgcac agtgtttcca 34740attctctata attaaagcca tagactttca tgtattgaaa aaagcaagaa ttgcattctt 34800gacagattct ttcattgcct taaaaagaat gactagcctt gggagtctgg gcagctgggt 34860ccagtgttgt agactttctc tctgctgagc cacagcttca aagatttgtc cttcttgttt 34920ccagggatct atttctcaga caataagtaa aggctttccc tggcctaatg tgctgtaagt 34980gaatgctact atatatgttc caggcactgg gctagagact aatatttaaa agccaggaaa 35040tttcctatag aaaatctata tctcagggtt ttctcaaaag agctgggaac tctggatgcc 35100cattcatgat tccagtagtt aaccagagta caagaagggc tgagtcttct cagatgggca 35160aacccactct ggctgactgc agatccacca agcctattgt cttagaccag gaccctttgg 35220caactcattc ccataagcct gtgacccttg ctttaaatat gcaggccttg tcttctctca 35280aaaagcacat caaggctgca gcgaatgcag atatcaaatg atgaagttaa aaacaaaagc 35340tttgctgggc gtggcagctc acacctgtaa tcctagcact ttgggaggct gaggcaggag 35400gatcacttta ggccagaggt tcaacaccag accttgtctc tcaaaaaata aaaaattcag 35460ctgggtgcgg tgtagttcct agccacttgg gaggctggga tggaaggatc ccttgaaccc 35520aggagttcaa ggctgcagtg ggccatgatt gcatcactgc acaggcgaca gaattagatc 35580ccatctctta aaaaaataaa aaatttaaaa gtgacttcaa aaatctatgc tgtgatggag 35640agatttttcc ttctgtatga ttgtgatagc tctgtggcct atgacgtcat caggttctgg 35700gcaaagtgta ggttttctgt ttctttgttt ttgaaaccat tgcacagtcc taagaaacat 35760cacattctgg gtcctgggca ccagccaaca tgaggtgagg gcaccagggt ttgctcattg 35820cattcttgac agattctctt attgccttaa aaagaatcac tggccttggg gagtctgtgg 35880ctggctgggt gcagtgttgt ggactctctc tgcagagtca tggagccttg ttcagaatgc 35940ttcctgagct gccctggttg gccaagggta aaaacagccc tgacttccct gcaagaaaca 36000ctgcagctgg gccagagagt cagcccatcc caggcatggg tttaaaaagt ggaggctttt 36060gtttgaaagc cctgctctaa ttttgtcctc actcaaacct ctgttcactt gatctgcttt 36120aggctccgag ggaacacttt ctctctagag gaggttgaca agctcggctg cagggacacc 36180agactcttgc tttgaagtct ccgggaggat gttcgtctca gtttgtttgt gagcaggctg 36240tgagtttggg ccccagaggc tgggtgacat gtgttggcag cctcttcaaa atgagccctg 36300tcctgcctaa ggctgaactt gttttctggg aacaccatag gtcaccttta ttctggcaga 36360ggagggagca tcagtgccct ccaggataga cttttcccaa gcctactttt gccattgact 36420tcttcccaag attcaatccc aggatgtaca aggacagccc ctcctccata gtatgggact 36480ggcctctgct gatcctccca ggcttccgtg tgggtcagtg gggcccatgg atgtgcttgt 36540taactgagtg ccttttggtg gagaggcccg gcctctcaca aaagacccct taccactgct 36600ctgatgaaga ggagtacaca gaacacataa ttcaggaagc agctttcccc atgtctcgac 36660tcatccatcc aggccattcc ccgtctctgg ttcctcccct cctcctggac tcctgcacac 36720gctccttcct ctgaggctga aattcagaat attagtgacc tcagctttga tatttcactt 36780acagcacccc caaccctggc acccagggtg ggaagggcta caccttagcc tgccctcctt 36840tccggtgttt aagacatttt tggaagggga cacgtgacag ccgtttgttc cccaagacat 36900tctaggtttg caagaaaaat atgaccacac tccagctggg atcacatgtg gacttttatt 36960tccagtgaaa tcagttactc ttcagttaag cctttggaaa cagctcgact ttaaaaagct 37020ccaaatgcag ctttaaaaaa ttaatctggg ccagaatttc aaacggcctc actaggcttc 37080tggttgatgc ctgtgaactg aactctgaca acagacttct gaaatagacc cacaagaggc 37140agttccattt catttgtgcc agaatgcttt aggatgtaca gttatggatt gaaagtttac 37200aggaaaaaaa attaggccgt tccttcaaag caaatgtctt cctggattat tcaaaatgat 37260gtatgttgaa gcctttgtaa attgtcagat gctgtgcaaa tgttattatt ttaaacatta 37320tgatgtgtga aaactggtta atatttatag gtcactttgt tttactgtct taagtttata 37380ctcttataga caacatggcc gtgaacttta tgctgtaaat aatcagaggg gaataaactg 37440ttg 3744341315DNAHomo sapiensIBD1prox cDNA 4cgatcagaag caggtcacac agcctgtttc ctgttttcaa acggggaact tagaaagtgg 60cagcccctcg gcttgtcgcc ggagctgaga accaagagct cgaaggggcc atatga cac 119 His 1tcc tcc cgg acc cct gga cac aca cag ccc tgg aga ctg gag cct tgg 167Ser Ser Arg Thr Pro Gly His Thr Gln Pro Trp Arg Leu Glu Pro Trp 5 10 15 agc atg gca agt cca gag cac cct ggg agc cct ggc tgc atg gga ccc 215Ser Met Ala Ser Pro Glu His Pro Gly Ser Pro Gly Cys Met Gly Pro 20 25 30 ata acc cag tgc acg gca agg acc cag cag gaa gca cca gcc act ggc 263Ile Thr Gln Cys Thr Ala Arg Thr Gln Gln Glu Ala Pro Ala Thr Gly 35 40 45 ccc gac ctc ccg cac cca gga cct gac ggg cac tta gac aca cac agt 311Pro Asp Leu Pro His Pro Gly Pro Asp Gly His Leu Asp Thr His Ser 50 55 60 65ggc ctg agc tcc aac tcc agc atg acc acg cgg gag ctt cag cag tac 359Gly Leu Ser Ser Asn Ser Ser Met Thr Thr Arg Glu Leu Gln Gln Tyr 70 75 80 tgg cag aac cag aaa tgc cgc tgg aag cac gtc aaa ctg ctc ttt gag 407Trp Gln Asn Gln Lys Cys Arg Trp Lys His Val Lys Leu Leu Phe Glu 85 90 95 att gct tca gct cgc atc gag gag aga aaa gtc tct aag ttt gtg gtg 455Ile Ala Ser Ala Arg Ile Glu Glu Arg Lys Val Ser Lys Phe Val Val 100 105 110 tac caa atc atc gtc atc cag act ggg agc ttt gac aac aac aag gcc 503Tyr Gln Ile Ile Val Ile Gln Thr Gly Ser Phe Asp Asn Asn Lys Ala 115 120 125 gtc ctg gaa cgg cgc tat tcc gac ttc gcg aag ctc cag aaa gcg ctg 551Val Leu Glu Arg Arg Tyr Ser Asp Phe Ala Lys Leu Gln Lys Ala Leu130 135 140 145ctg aag acg ttc agg gag gag atc gaa gac gtg gag ttt ccc agg aag 599Leu Lys Thr Phe Arg Glu Glu Ile Glu Asp Val Glu Phe Pro Arg Lys 150 155 160 cac ctg act ggg aac ttc gct gag gag atg atc tgt gag cgt cgg cgc 647His Leu Thr Gly Asn Phe Ala Glu Glu Met Ile Cys Glu Arg Arg Arg 165 170 175 gcc ctg cag gag tac ctg ggc ctg ctc tac gcc atc cgc tgc gtg cgc 695Ala Leu Gln Glu Tyr Leu Gly Leu Leu Tyr Ala Ile Arg Cys Val Arg 180 185 190 cgc tcc cgg gag ttc ctg gac ttc ctc acg cgg ccg gag ctg cgc gag 743Arg Ser Arg Glu Phe Leu Asp Phe Leu Thr Arg Pro Glu Leu Arg Glu 195 200 205 gct ttc ggc tgc ctg cgg gcc ggc cag tac ccg cgc gcc ctg gag ctg 791Ala Phe Gly Cys Leu Arg Ala Gly Gln Tyr Pro Arg Ala Leu Glu Leu210 215 220 225ctg ctg cgc gtg ctg ccg ctg cag gag aag ctc acc gcc cac tgc cct 839Leu Leu Arg Val Leu Pro Leu Gln Glu Lys Leu Thr Ala His Cys Pro 230 235 240 gcg gcc gcc gtc ccg gcc ctg tgc gcc gtg ctg ctg tgc cac cgc gac 887Ala Ala Ala Val Pro Ala Leu Cys Ala Val Leu Leu Cys His Arg Asp 245 250 255 ctc gac cgc ccc gcc gag gcc ttc gcg gcc gga gag agg gcc ctg cag 935Leu Asp Arg Pro Ala Glu Ala Phe Ala Ala Gly Glu Arg Ala Leu Gln 260 265 270 cgc ctg cag gcc cgg gag ggc cat cgc tac tat gcg cct ctg ctg gac 983Arg Leu Gln Ala Arg Glu Gly His Arg Tyr Tyr Ala Pro Leu Leu Asp 275 280 285 gcc atg gtc cgc ctg gcc tac gcg ctg ggc aag gac ttc gtg act ctg 1031Ala Met Val Arg Leu Ala Tyr Ala Leu Gly Lys Asp Phe Val Thr Leu290 295 300 305cag gag agg ctg gag gag agc cag ctc cgg agg ccc acg ccc cga ggc 1079Gln Glu Arg Leu Glu Glu Ser Gln Leu Arg Arg Pro Thr Pro Arg Gly 310 315 320 atc acc ctg aag gag ctc act gtg cga gaa tac ctg cac tga 1121Ile Thr Leu Lys Glu Leu Thr Val Arg Glu Tyr Leu His 325
330 gccggcctgg gaccccgcag ggacgctgga gatttggggt caccatggct cacagtgggc 1181tgtttggggt tctttttttt tatttttcct tttctttttt gttatttgag acagtcttgc 1241tctgtcaccc agactgaagt gcagtggctc aattatgtct cactgcagcc tcaaactcct 1301gggcacaagc aatc 13155334PRTHomo sapiensIBD1prox 5His Ser Ser Arg Thr Pro Gly His Thr Gln Pro Trp Arg Leu Glu Pro 1 5 10 15 Trp Ser Met Ala Ser Pro Glu His Pro Gly Ser Pro Gly Cys Met Gly 20 25 30 Pro Ile Thr Gln Cys Thr Ala Arg Thr Gln Gln Glu Ala Pro Ala Thr 35 40 45 Gly Pro Asp Leu Pro His Pro Gly Pro Asp Gly His Leu Asp Thr His 50 55 60 Ser Gly Leu Ser Ser Asn Ser Ser Met Thr Thr Arg Glu Leu Gln Gln 65 70 75 80 Tyr Trp Gln Asn Gln Lys Cys Arg Trp Lys His Val Lys Leu Leu Phe 85 90 95 Glu Ile Ala Ser Ala Arg Ile Glu Glu Arg Lys Val Ser Lys Phe Val 100 105 110 Val Tyr Gln Ile Ile Val Ile Gln Thr Gly Ser Phe Asp Asn Asn Lys 115 120 125 Ala Val Leu Glu Arg Arg Tyr Ser Asp Phe Ala Lys Leu Gln Lys Ala 130 135 140 Leu Leu Lys Thr Phe Arg Glu Glu Ile Glu Asp Val Glu Phe Pro Arg 145 150 155 160 Lys His Leu Thr Gly Asn Phe Ala Glu Glu Met Ile Cys Glu Arg Arg 165 170 175 Arg Ala Leu Gln Glu Tyr Leu Gly Leu Leu Tyr Ala Ile Arg Cys Val 180 185 190 Arg Arg Ser Arg Glu Phe Leu Asp Phe Leu Thr Arg Pro Glu Leu Arg 195 200 205 Glu Ala Phe Gly Cys Leu Arg Ala Gly Gln Tyr Pro Arg Ala Leu Glu 210 215 220 Leu Leu Leu Arg Val Leu Pro Leu Gln Glu Lys Leu Thr Ala His Cys 225 230 235 240 Pro Ala Ala Ala Val Pro Ala Leu Cys Ala Val Leu Leu Cys His Arg 245 250 255 Asp Leu Asp Arg Pro Ala Glu Ala Phe Ala Ala Gly Glu Arg Ala Leu 260 265 270 Gln Arg Leu Gln Ala Arg Glu Gly His Arg Tyr Tyr Ala Pro Leu Leu 275 280 285 Asp Ala Met Val Arg Leu Ala Tyr Ala Leu Gly Lys Asp Phe Val Thr 290 295 300 Leu Gln Glu Arg Leu Glu Glu Ser Gln Leu Arg Arg Pro Thr Pro Arg 305 310 315 320 Gly Ile Thr Leu Lys Glu Leu Thr Val Arg Glu Tyr Leu His 325 330 68135DNAHomo sapiensexon(1)..(161)exon(3812)..(3950)exon(5426)..(5577)exon(7273)..(813- 5) 6cgatcagaag caggtcacac agcctgtttc ctgttttcaa acggggaact tagaaagtgg 60cagcccctcg gcttgtcgcc ggagctgaga accaagagct cgaaggggcc atatgacact 120cctcccggac ccctggacac acacagccct ggagactgga ggtcagtatt tgatcccaag 180ctcagctgtc ctctgcctgc tgtggcctga gtccccttct cctggggccc tgcctggcac 240ctgctggggg cagggtggga gggggaagag ttagtgacag ccgctgtgtc tggagctctc 300cttagcacac tgaggcagag gaagggacag ctcctggacc ttccatcacc tccattcctt 360ttgaaatgct aggcgcttgt acaacccatc ttgggcctgg agaataagtc accacacctg 420tgtttctcaa aagaacagtg tcagggaacc cctgcctcag cacagcctta gaggactcat 480ggaaaatgca gaatccaggc ctgttcaatg gcaccttcct atgttagcag ccaggaaacc 540tgctcttgga caagcccctg ggatcccacc cccaccccac caggggattc ttacacacac 600tgggttggga gcccctggct ttggcaaggc ttctcaggtg agcgtccagt tgttggaggg 660tacccaccct ttccccaaga gaggcagcca cacatccaac atcctgggat ctctgtctcc 720cagcgtgggc catgtgcttt atttcacccc ctagaggctc atcccccatg aaaagtcctc 780cgcaggccct cagaaagata gtgtggcctc tgtgtgccca gcagaagaag gactggactt 840ggcagtcagc tcttggagag ggggtggtta ggacacctgg ggacaggagg aggagaatga 900ctgtctgtgc acacacggct ggaaggtaca ggaggctggg aagctgctct gtcccctggg 960ccaactacag gcccccaggc caacagcaac aacactttta gtattttgtt ataaagtcaa 1020gaaatctttg ctacagaggg tgaggagagg gaaggaaagg gccatggaac cgtctatgtg 1080gctatcccca gagagctttt agagtgacag gattgctttc ccatttcaca gatgaggaaa 1140ctgaggcctg gagagggatg ggaagctacc caaggcccca tggatacacc agtgcacaac 1200tctttccttc cccctcctct ttaaatgggt gattcccaat gaaacctgta agagacaacc 1260ataagggagc tgactgtggc tgctgaattt gattttattc taaggcctgg ttttataatc 1320agctttctca gtctttactg gagtgtcaag ccgaggcatc atttctaggg tcttacaggg 1380tctctgggcc aatagtgccc tgcttctgac ctggagccag ctgcctggtc atgaaagcag 1440atctgcaaag gctggggccc ctgaggccaa ggccactcgc catcacccat tttacagaag 1500tgctgagcat aggagtgccc tgggccccca agaatcccag ccaccaagaa tcacgtaaac 1560catccactgt ctcacttagg caccagtcag aatgtaggga acccacccct agtcatccat 1620catcttatca acaggacggg gcttgtagcc acatttatca ggtagggaaa ctgaagccta 1680gagatattaa agcacttgct taaggacaca cggttggtca ggatggaagg cgatgtctcc 1740tgactccctg acaggcacaa gagacaagcg agaggtgccc gtgacggcat gctcaagaac 1800gtgcagccct gggccagcca ggcccctgct ccgtgcctct gtttgcccat ctgtaaaagg 1860tgaggttgga tcgagggtcc ctgagggccg cccactggat ggctgtgcag agccaaacgg 1920agaaggcccc agggttcctt tcacccgaca cagcaagcac ttccccctga agtgcaggct 1980ccaggcccca gctgacctcc cctctcccag gccagcggct ctcacccctg gagcaaggga 2040caggcgctgg ctgtgctcag ggacatgcat gactcccgcc cccatctgtg ctcagggggt 2100gccagggagg cactggctct atctttctct aggccgtagt cagcccaggg gttcagacca 2160agagcccaga atccaacaga tcagagttca agtcccagct ctacctctat gttccactgg 2220cagcttcctc aggtcatttg caccttcctt gtcttgaatt tccatgccta accagtatac 2280cagctactcc ctccagccga tctaatgttt taattgtccc tttctctaag ttgtctcaaa 2340catttgtaat tctattccaa tccaccttaa tttagtcatt tatttcacaa atatttctgg 2400aaacatctag cacttaacag acactaaaag cgggggtact acacagtccc tgggatggac 2460agggccctga gctgaggctt cagagtctgc ctgactgaat cctcacccca gccttgtgaa 2520cgtgggttct gttattatcc ccaatttata ggaaacagaa gcacagagaa gttgagtcac 2580ttgccagcta ccaggtcatc ccttccactt atccgggtca cagacagagt tattatgtaa 2640accagatccc agctgcctgt tctccctccc tgagtaaggt ggagagaatt ctgaagtcag 2700cccagcctgg gtctgtatcc tgcccaccac tcaccagctc ctcatctttg gcaactctaa 2760gtctcagttc ccttatcata aaagggagat gtaaacagtc ctgagtgcag acagtgttca 2820ggttagtgca agagtgtgtg ctgggtgtga agtgcacagc cagcacgtca caagcactgg 2880agacaaattc agctttgctt gttgcgcaca ctcaccagct gcgtgacttt agacctcagt 2940tttctcatct gttatgtggt ggtaatgata gacttttgtg agcattaaac tagattaggg 3000gctatggaga acctagatgg gtatgaagtg ggtataataa gctatcagtt aattttgctg 3060atagatagat tattgattga ttgatcgata gaagattcat accagtatct acctgctctg 3120aacactgacc tttctttttt tctttttgag atggtcttgt tctgtcaccc agactggagt 3180gcagtggcat catcatagct cactgcagcc tcagtctctt gggcttaagg gatcctcctg 3240tctcagcctc ccaagtagct gggaccacag gcgtgcatcc tggataattt ttttttattt 3300tttctagaga cggggtctca ctacattggc caggctggtc tcaaattcct gggctcaagt 3360gatccttcta acccagcctc ccaaagcgct gggattacag gcatgagtgg ccatgttcaa 3420cttgaacact gagacttcat tcgcatgtgt aacataaaac tgagtatcta gacaagccag 3480catctttctt tcaagtaatc actaaagcca atacttttac ttgaaatcat ctcatttaaa 3540actctgagca atacgtaagg atcacctcaa taacatatgg atcatcgcaa taggtgaagg 3600gtcttctctg ccttggagta acctgcccag caaaggggca gacccagatt tgggatctgg 3660cagctgggag agtggggaag gttgagccgt ggggcccttg tcattccctc tgcctgccag 3720gagggggcat gacacagctc ctaggcaccc caggagccac cgggaacccc aactggagtg 3780ggtcctcact gttctctttt tcctctggca gccttggagc atggcaagtc cagagcaccc 3840tgggagccct ggctgcatgg gacccataac ccagtgcacg gcaaggaccc agcaggaagc 3900accagccact ggccccgacc tcccgcaccc aggacctgac gggcacttag gtgggcttga 3960ggcttgagac tcggtctggg ggagaggtct gaagacattc aaagtacaaa tgtgggtcac 4020tttgggggat gcagcaagag gcccgggcag ctcttgtaac ttgggttatc ccaaaacaga 4080cactgagaca cagatctagt gcaagctgtt tatccgggag acggtcctag gagtcatggc 4140aggggagtgg gaatggaagg aaagggcaag aggccagggc aggacatcag tgaacagata 4200ggcacggtag gtggctgaag ctcaacccca gcgggggtct tctgggagac cctggaacat 4260atctctgggt tgtcctatcc taggggtgag gaagccgggc tgttatctac cagtcctgcc 4320ctgcatagga gaagggacgc tcctgggcct gctgctatgg ccctagaaag ccctcaggga 4380agccagtggc atgttctgga aaagtgggtg ccaagagggc acggtccagc ctggggcatg 4440gacagcatct gctgtagtgc catctcctgg aacagatctt ttcttacagt ccttcgagat 4500gccctattca atacctgctc tgttcctggc cctatgcagg gcactggaga aacagaaaca 4560ggaagaaatc aaacactgca ctagtcctga ggtttggtag agaaacagat cagtgagaaa 4620cagttacacg tgccacgaga aataaataaa taaaatgaaa aacctgtagg aacaaggtgg 4680gaagctctta ctctaatgcc aaggggcatt tgcagtgatg tgggggctgg gtcttgaagg 4740gtagactgga aaagggctgg gacccatgcc ctttgcaata aaatgcacaa ttatttgtgc 4800ttcttaagaa cctcagagtg gcgcagggct caagtggggt ttaagaaaca ctgtgttcgt 4860tttccaggcg tggaaataga gggttggatg caaggcagag cagtgcacgt ccgagaagag 4920cccggcatgt gggcagttag atgagaaggt taggaagggc cagcccgctg aggctggaac 4980ataacatcct cctcactgcc tcccctgccc actgatgtgt gctcaaggag tcgtggcaac 5040agtcacgaag tcagggctgc agggagcaca gaaacacaca agccaccgtc tctgcttgtc 5100cagagcaggg atttcaccat ggccaatcta cagaccagaa gtggacgatg caaagtgccc 5160gcaccgcatt ccaaagctgt gaaaccactt gggggtgatg ggctatttgg gattgtcggt 5220ggtagggtgg attctgccag gctgggcaca gaggtctgtc tgatgcccca attgggccta 5280taaatggcgg ggtgggagag agggatattc aatactcttc aggagttctg atatgccatc 5340tcagatagac ccagccatct ccccaagccc atgcctcgga agtgcactga cagggtgcag 5400atccttaagg gtgttgtcct tccagacaca cacagtggcc tgagctccaa ctccagcatg 5460accacgcggg agcttcagca gtactggcag aaccagaaat gccgctggaa gcacgtcaaa 5520ctgctctttg agatcgcttc agctcgcatc gaggagagaa aagtctctaa gtttgtggta 5580agcagagatt gggaaatggt ggagcctctt tcactctgct tccttcctgg ccctgaataa 5640gtcttgtaga gcctcaggtt tcccaactat gaaatgggtc aacacactaa ctcacagctt 5700tcttctggag aaaatggcca aagagcaaga tttcaggctc agcacctgct agggtctgtg 5760aggattcgaa ccatataagt catatttctt ggtcccaaga aggaaatagc ccagtttaat 5820cccatcttat caggtgtcag tcacctgtgt cctttcttca ccaattttgc catatcactg 5880tatctgttct aattattatt acttattttt ttctttaaat tggatcactt tttaaaaaca 5940tgaagcacat ttatttcaaa gagaaatacc ttaaatggaa aaccaatatc acatggcaca 6000aagcaaaagt aacatactag aaaagtcgat acaaggaaag tcaatacaag gaaagctatg 6060tgctgttatt aaattctagc tggttactgt ggcttcggga aagccctgtg cctgggagct 6120gctcctctcc ctgttagaat ggaattttag cttgtgttaa gggatgttaa agactgccta 6180agagccacac ttcatccttc tccttcactt acctgggacc gggataaata acatagctac 6240cactgaatgc caatggcatg ccgggcacag ctccatgtgg tttcagtgca ttaactcatt 6300taatcctcac tgggtgaggt aggcactatg cctatccttg ttttatgaat gagaaaagtg 6360agactcggag aggttaaatt actcatctaa aaccacacag ctagaccatg gtagggctat 6420aattacaacc catgcaatct ggctctggag tcagatgcat gggttataat tgcccttaat 6480atataattgc ccgtaatcag gattctcttg aaagatgatt gaaaaggatt gattttctta 6540ccatataacg gcatcaccag tgtacctaaa tgatgttata ttgtacgtaa aactaattcc 6600caagtgtgaa acatttggaa aacacagcat ctcagttcag aaaacagagg cccagtttta 6660gcaagtaaag ccaagaggga ccccagcagc ctgcagggca ggaccctctg ccctttctcc 6720tcccagatgt ccccaccttg ctgtgttgtt gttccagggt tgactcagct gatgccaata 6780gcaatttaaa acagaattgg gccaggtgca gtggctcatg cctgtaatcc cagcactttg 6840ggaggcccag gtaggaggat cgcttgagcc caggagttgg agaccagcct gggcaacaca 6900gccagacccc atcttttaaa aagaatcaaa aaatctgcca ggtagtgggt gtgcctgtag 6960tcccagctac tcaggaggct caggtgggca ggtcaattga gcccataagt tcaaggttgc 7020agtgaggtat gatcgcatca ctgtactcca gcctgggtaa cagtgcgaga ccctgtctct 7080aaaaataaat aaataaataa ataaataaat aaataaacaa acaaacaaac aaacaaacaa 7140tcaattgcat ataaggatcg cccgttttca gggcatgctt tacaccggcc tggttaactt 7200tactctgggt gtgctccgtc cgccgcagcc cccgccggga ggtggccaca gctctctctg 7260gttgcgccct aggtgtacca aatcatcgtc atccagactg ggagctttga caacaacaag 7320gccgtcctgg aacggcgcta ttccgacttc gcgaagctcc agaaagcgct gctgaagacg 7380ttcagggagg agatcgaaga cgtggagttt cccaggaagc acctgactgg gaacttcgct 7440gaggagatga tctgtgagcg tcggcgcgcc ctgcaggagt acctgggcct gctctacgcc 7500atccgctgcg tgcgccgctc ccgggagttc ctggacttcc tcacgcggcc ggagctgcgc 7560gaggctttcg gctgcctgcg ggccggccag tacccgcgcg ccctggagct gctgctgcgc 7620gtgctgccgc tgcaggagaa gctcaccgcc cactgccctg cggccgccgt cccggccctg 7680tgcgccgtgc tgctgtgcca ccgcgacctc gaccgccccg ccgaggcctt cgcggccgga 7740gagagggccc tgcagcgcct gcaggcccgg gagggccatc gctactatgc gcctctgctg 7800gacgccatgg tccgcctggc ctacgcgctg ggcaaggact tcgtgactct gcaggagagg 7860ctggaggaga gccagctccg gaggcccacg ccccgaggca tcaccctgaa ggagctcact 7920gtgcgagaat acctgcactg agccggcctg ggaccccgca gggacgctgg agatttgggg 7980tcaccatggc tcacagtggg ctgtttgggg ttcttttttt ttatttttcc ttttcttttt 8040tgttatttga gacagtcttg ctctgtcacc cagactgaag tgcagtggct caattatgtc 8100tcactgcagc ctcaaactcc tgggcacaag caatc 8135716DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3120 (AFM326vc5) polymorphism marker 7ctgggtgcga ttgctc 16816DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3120 (AFM326vc5) polymorphism marker 8ccaggcccca tgacag 16925DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S298 (AFMa189wg5) polymorphism marker 9tggtcccggc ccaatcccaa tgctt 251028DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S298 (AFMa189wg5) polymorphism marker 10ttcctcatgt ataaattggg tgtggcca 281125DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S299 polymorphism marker 11acagagtgag gaccccatct ctatc 251225DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S299 polymorphism marker 12tccaactgct gggattacag gcaca 251322DNAArtificial SequenceDescription of Artificial SequencePCR primer for SPN polymorphism marker 13agtccccgag accagggcaa ac 221423DNAArtificial SequenceDescription of Artificial SequencePCR primer for SPN polymorphism marker 14tccatttctg cagtacacat gca 231520DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S383 polymorphism marker 15ctctccccat agaaggcatc 201620DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S383 polymorphism marker 16ggatagagac gttctcttaa 201720DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S753 (GGAA3G05) polymorphism marker 17caggctgaat gacagaacaa 201820DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S753 (GGAA3G05) polymorphism marker 18attgaaaaca actccgtcca 201925DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3044 (AFMa222za9) polymorphism marker 19atactcactt ttagacagtt caggg 252021DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3044 (AFMa222za9) polymorphism marker 20ggctcagttc ctaaccagtt c 212120DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S409 (AFM161xa1) polymorphism marker 21agtcagtctg tccagaggtg 202220DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S409 (AFM161xa1) polymorphism marker 22tgaatcttac atcccatccc 202317DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3105 (AFMb341zc5) polymorphism marker 23gatcttccca aagcgcc 172417DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3105 (AFMb341zc5) polymorphism marker 24tcccgtcagc caagcta 172520DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S261 (MFD24) polymorphism marker 25aagcttgtat ctttctcagg 202620DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S261 (MFD24) polymorphism marker 26atctaccttg gctgtcattg 202720DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S540 (GATA7B02) polymorphism marker 27cctccataat catgtgagcc 202820DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S540 (GATA7B02) polymorphism marker 28aatctcccca actcaagacc 202920DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3080 (AFMb068zb9) polymorphism marker 29ggatgcctgc tctaaatacc 203019DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3080 (AFMb068zb9) polymorphism marker 30cccaggggtc aaacttaat 193121DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S517 (AFMa132we9) polymorphism marker 31ggtttgaaag tatctccagg g 213221DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S517 (AFMa132we9) polymorphism marker 32ggtttgaaag tatctccagg g 213320DNAArtificial SequenceDescription of Artificial SequencePCR primer
for D16S411 (AFM186xa3) polymorphism marker 33gtgcatgtgt tcgtatcaac 203420DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S411 (AFM186xa3) polymorphism marker 34tcatctccaa aggagtttct 203518DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3035 (AFMa189wg5) polymorphism marker, PCR or ligation oligonucleotide primer for D16S3035 biallelic polymorphism marker 35aaagccaacc ttgcttca 183620DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3035 (AFMa189wg5) polymorphism marker, PCR or ligation oligonucleotide primer for D16S3035 biallelic polymorphism marker 36tcttggaaac aggtaagtgc 203718DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3136 (AFMa061xe5) polymorphism marker, PCR or ligation oligonucleotide primer for D16S3136 biallelic polymorphism marker 37attgccctca agaacagc 183817DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3136 (AFMa061xe5) polymorphism marker, PCR or ligation oligonucleotide primer for D16S3136 biallelic polymorphism marker 38gtgctatgcc atcccag 173920DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S541 (GATA7E02) polymorphism marker 39ccacaccagc gtttttctaa 204024DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S541 (GATA7E02) polymorphism marker 40cacactttac acacacctat accc 244122DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3117 (AFM288wb1) polymorphism marker 41aagccatatt aggtctgtcc at 224219DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S3117 (AFM288wb1) polymorphism marker 42gcttgggtta aatgcgtgt 194320DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S416 (AFM210yg3) polymorphism marker 43agcagtttgg gtaaacattg 204420DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S416 (AFM210yg3) polymorphism marker 44aaatatgcct tctggaggtg 204520DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S770 (GGAA20G02) polymorphism marker 45ggaggatcag gggagtttat 204624DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S770 (GGAA20G02) polymorphism marker 46caaagtaaat gaatgtctac tgcc 244723DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S2623 (GATA81B12) polymorphism marker 47ccaactctgt agtttcaaag agc 234820DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S2623 (GATA81B12) polymorphism marker 48tcacagccta cttgcttggt 204925DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S390 polymorphism marker 49gacagcctca aatgaaatat aacac 255025DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S390 polymorphism marker 50gctctcagct agggtagttg tttat 255125DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S419 (AFM225zf2) polymorphism marker 51atttttaagg aatgtaaagn acaca 255220DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S419 (AFM225zf2) polymorphism marker 52gaccaggagt cagtaaaagg 205320DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S771 (GGAA23C09) polymorphism marker 53gtccaaaaca ccaccctcta 205424DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S771 (GGAA23C09) polymorphism marker 54gaagtagatc agtcatcttg ctgc 245519DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S408 (AFM137xf8) polymorphism marker 55tcctctgggg gattcactc 195620DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S408 (AFM137xf8) polymorphism marker 56gggacatcac caagcacaag 205725DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S508 (AFM304xf1) polymorphism marker 57caggaaaata aatctaacac acata 255820DNAArtificial SequenceDescription of Artificial SequencePCR primer for D16S508 (AFM304xf1) polymorphism marker 58cctgtgggca ctgataaata 205919DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ADCY7int7 biallelic polymorphism marker 59cccagccccc atctcaccg 196019DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ADCY7int7 biallelic polymorphism marker 60cccagccccc atctcacca 196119DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ADCY7int7 biallelic polymorphism marker 61ctgcggagga ggctgctgg 196219DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for hb133D1f biallelic polymorphism marker 62tcactcccac caccctttc 196320DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for hb133D1f biallelic polymorphism marker 63agaagtttag tgtggcgtgg 206417DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg35ExC biallelic polymorphism marker 64gccatctccc caagccc 176518DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg35ExC biallelic polymorphism marker 65tcgatgcgag ctgaagcg 186618DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg35ExC biallelic polymorphism marker 66tcgatgcgag ctgaagca 186720DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for CTG35ExA biallelic polymorphism marker 67tgaatgttaa agggctctgg 206819DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for CTG35ExA biallelic polymorphism marker 68ttggttctca gctccggcg 196919DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for CTG35ExA biallelic polymorphism marker 69ttggttctca gctccggca 197019DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for Ctg25Ex1 biallelic polymorphism marker 70agaaaccggg ctggctgtg 197121DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for Ctg25Ex1 biallelic polymorphism marker 71gcattgcctt ttgatctcta c 217218DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for SNP3-2931 biallelic polymorphism marker 72tgggctcttc tgcgggga 187318DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for SNP3-2931 biallelic polymorphism marker 73tgggctcttc tgcggggg 187420DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for SNP3-2931 biallelic polymorphism marker 74tgcctcttct tctgccttcc 207522DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg2931-5ag/ola biallelic polymorphism marker 75cgagctgtac ctgaggaagc gt 227624DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg2931-5ag/ola biallelic polymorphism marker 76cctgagctgt acctgaggaa gcgc 247720DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg2931-5ag/ola biallelic polymorphism marker 77catcatgagc ccggggtggc 207823DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg2931-3ac/ola biallelic polymorphism marker 78tttctcttgg cttcctggtg cgt 237925DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg2931-3ac/ola biallelic polymorphism marker 79accttctctt ggcttcctgg tgcgg 258026DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for ctg2931-3ac/ola biallelic polymorphism marker 80gccaaaggtg tcgtgccagg gctcca 268120DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for SNP1 biallelic polymorphism marker 81atctgagaag gccctgctct 208220DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for SNP1 biallelic polymorphism marker 82atctgagaag gccctgctcc 208319DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for SNP1 biallelic polymorphism marker 83cccacactta gccttgatg 198419DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for Ctg22Ex1 biallelic polymorphism marker 84atgagttagc ccagcggag 198519DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for Ctg22Ex1 biallelic polymorphism marker 85attgagagcc cttggagtg 198619DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for hb27G11F biallelic polymorphism marker 86tgatttcgta agacaagtg 198720DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for hb27G11F biallelic polymorphism marker 87agcaaattct aggagttatg 208819DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for KIAA0849ex9 biallelic polymorphism marker 88agctgagatg tccggatcg 198918DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for KIAA0849ex9 biallelic polymorphism marker 89agctgagatt ccggatca 189020DNAArtificial SequenceDescription of Artificial SequencePCR or ligation oligonucleotide primer for KIAA0849ex9 biallelic polymorphism marker 90gtcctcttaa cttcccttcc 20
Patent applications by Gilles Thomas, Paris FR
Patent applications by Jean Pierre Hugot, Paris FR
Patent applications by Mathias Chamaillard, Joue-Les-Tours FR
Patent applications by Mohamed Zouali, Bagneux FR
Patent applications by Suzanne Lesage, Sainte-Honorine FR
Patent applications by FONDATION JEAN DAUSSET-CEPH
Patent applications in class Nucleotides or polynucleotides, or derivatives thereof
Patent applications in all subclasses Nucleotides or polynucleotides, or derivatives thereof